JPWO2007026960A1 - Therapeutic or diagnostic use of MOCS3 gene - Google Patents

Abstract

The present invention uses a cancer therapeutic agent containing a MOCS3 protein expression inhibitor or activity inhibitor; a screening method for a compound that can be used as an active ingredient of such a therapeutic agent; an antibody against MOCS3 protein; Provide cancer diagnostic agents and cancer diagnosis methods.

Description

  The present invention relates to the MOCS3 gene, which is a gene specifically amplified in cancer, its therapeutic or diagnostic use, and the like.

Malignant tumors (cancers) are characterized by lethality due to generalization through proliferation, invasion, and metastasis. Local therapies such as surgical resection or radiotherapy cannot adequately address metastatic recurrence cancer, and the development of systemic pharmacotherapy is expected to improve the outcome of cancer treatment in the future. Yes.
Chemotherapy, which is the current center of cancer drug therapy, often uses cell killing agents that directly act on the DNA and / or RNA of cancer cells and cause the cells to die. It also acted on normal cells such as bone marrow cells, germ cells, hair matrix cells, and gastrointestinal epithelial cells, and had strong side effects. On the other hand, recent advances in molecular cell biology have elucidated the mechanisms involved in cancer cell invasion, proliferation, and metastasis, and attention has been focused on the development of molecular targeted drugs that specifically act on the specific mechanisms of cancer cells. ing. As a representative example, Iressa (generic name: gefitinib) which is an EGFR (epidermal growth factor receptor) tyrosine kinase inhibitor effective in the treatment of non-small cell lung cancer (WO 96/33980), effective in the treatment of breast cancer, Herceptin (generic name: trastuzumab), a humanized monoclonal antibody of HER-2 (human epidermal growth factor receptor 2) (WO94 / 00136), and the like. However, there are still few effective molecular targeted drugs at present, and further development of effective molecular targeted drugs for each cancer type is desired in the future.
Japanese colon cancer tends to increase year by year, and the number of deaths is third after lung cancer and stomach cancer. By age group, people in their 60s are the most frequent, followed by those in their 50s and 70s. The cause of the increase in colorectal cancer may be genetic factors, environmental factors, etc., but it has been pointed out that it is caused by westernization of dietary habits, especially excessive consumption of animal fat. The development of an effective molecular target drug for colorectal cancer is awaited. In addition, about half of the tumor markers (CEA, CA19-9) used for diagnosis are positive even in advanced colorectal cancer, and there is no organ specificity, and development of a higher performance diagnostic agent has been made. It is desired.

Under such circumstances, there is a need for new drugs or methods for treating and / or diagnosing cancer.
In particular, there is a need for therapeutic and / or diagnostic agents with high specificity for cancer.
In view of the above situation, as a result of intensive studies, the present inventors have found that a gene that is frequently amplified in cancer (for example, colorectal cancer) is the MOCS3 gene. . Furthermore, the present inventors have found that the growth of cancer cells can be suppressed by inhibiting the expression of MOCS3 protein in colorectal cancer cell lines and cervical cancer cell lines, and the present invention has been completed. . That is, the present invention provides the following cancer therapeutic agents, screening methods for candidate substances having a cancer inhibitory effect, cancer diagnostic agents, cancer diagnostic kits, cancer diagnostic methods, and the like.
(1) A cancer therapeutic agent containing a MOCS3 gene expression inhibitor as an active ingredient.
(2) The MOCS3 gene expression inhibitor is
(A) a nucleic acid having an action of inhibiting the expression of the MOCS3 gene by the RNAi effect,
(B) an antisense nucleic acid for the MOCS3 gene or a part thereof, or a transcript thereof,
(C) a decoy nucleic acid for the MOCS3 gene or a part thereof,
(D) a MOCS3 gene variant that acts dominantly on the MOCS3 gene or a portion thereof (e) a nucleic acid having a ribozyme activity that specifically cleaves a transcript of the MOCS3 gene,
And (f) a compound that inhibits transcription of the MOCS3 gene or translation of MOCS3 mRNA (excluding the nucleic acid)
The cancer therapeutic agent according to (1) above, comprising a substance selected from the group consisting of:
(3) A cancer therapeutic agent containing a MOCS3 protein activity inhibitor as an active ingredient.
(4) The MOCS3 protein activity inhibitor is
(A) an antibody against the MOCS3 protein,
(B) a MOCS3 protein variant having dominant negative properties for the MOCS3 protein; and
(C) Compound that binds to the MOCS3 protein (excluding the antibody and the mutant)
The cancer therapeutic agent according to (3) above, comprising a substance selected from the group consisting of:
(5) The cancer therapeutic agent according to any one of (1) to (4), wherein the cancer is colorectal cancer or cervical cancer.
(6) A method of screening for an expression inhibitor of MOCS3 gene,
(A) contacting a test compound with a cell expressing the MOCS3 gene;
(B) A screening method comprising the step of measuring the expression level of the MOCS3 gene, and (c) selecting a compound that decreases the expression level as compared with the case where the test compound is not contacted.
(7) A method for screening an activity inhibitor of MOCS3 protein,
(A) contacting the MOCS3 protein with a test compound;
(B) A screening method comprising a step of measuring the binding activity between the MOCS3 protein and a test compound, and (c) selecting a compound that binds to the MOCS3 protein.
(8) The method according to (6) or (7) above, wherein the cancer is colorectal cancer or cervical cancer.
(9) An antibody against the MOCS3 protein.
(10) A cancer therapeutic agent containing the antibody according to (9) above.
(11) The cancer therapeutic agent according to (10), further comprising a radioisotope, a therapeutic protein, a low molecular drug, or a vector carrying a therapeutic gene.
(12) The cancer therapeutic agent according to (10) or (11), wherein the cancer is colorectal cancer or cervical cancer.
(13) A cancer diagnostic agent comprising the antibody according to (9).
(14) A cancer diagnostic agent comprising a base sequence capable of hybridizing under stringent hybridization conditions to the MOCS3 gene or a partial base sequence thereof.
(15) The cancer diagnostic agent according to (13) or (14) above, wherein the cancer is colon cancer.
(16) A kit for cancer diagnosis containing the antibody according to (9).
(17) A cancer diagnostic kit comprising a polynucleotide comprising a nucleotide sequence capable of hybridizing under stringent hybridization conditions to the MOCS3 gene or a partial nucleotide sequence thereof.
(18) The cancer diagnostic kit according to (16) or (17), wherein the cancer is colorectal cancer.
(19) A method for detecting and / or quantifying MOCS3 protein or MOCS3 gene in a biological sample derived from a subject as a cancer marker.
(20) The method according to (19) above, wherein the biological sample is whole blood, serum, or plasma.
(21) The method according to (19) or (20) above, wherein the MOCS3 protein is detected and / or quantified using a mass spectrometer.
(22) The method according to any one of (19) to (21) above, wherein the MOCS3 protein is detected and / or quantified using an anti-MOCS3 antibody.
(23) (a) a step of bringing a biological sample derived from a subject into contact with an antibody against the MOCS3 protein, and (b) a step of detecting and / or quantifying the binding between the antibody and the MOCS3 protein in the sample,
The diagnostic method according to (22) above, comprising
(24) (a) contacting a biological sample derived from a subject with a polynucleotide having a base sequence capable of hybridizing under stringent hybridization conditions to the base sequence of the MOCS3 gene or a fragment thereof; and (b) Detecting and / or quantifying the hybridization between the polynucleotide in the sample and the MOCS3 gene or a fragment thereof;
The method according to (19) or (20) above, comprising:
(25) The method according to any one of (19) to (24) for use in diagnosis of cancer.
(26) The method according to (25), wherein the cancer is colon cancer.
(27) A cancer treatment method comprising a step of administering a MOCS3 gene expression inhibitor to a patient.
(28) A method for treating cancer, comprising a step of administering a MOCS3 protein activity inhibitor to a patient.
(30) Use of a MOCS3 gene expression inhibitor for the manufacture of a medicament for treating cancer.
(31) Use of a MOCS3 protein activity inhibitor for the manufacture of a medicament for treating cancer.
The present invention provides novel drugs, kits and methods useful for the treatment and / or diagnosis of cancer, particularly colorectal cancer, and methods for screening candidate compounds having a cancer suppressive action.

FIG. 1 is a histogram showing the frequency of the MOCS3 gene with respect to the degree of gene amplification in 200 specimens derived from colorectal cancer patients.
FIG. 2 is an optical micrograph (phase contrast image) showing the result of RNAi analysis when siRNA of MOCS3 gene was transfected into colon cancer cell line RKOE6.
FIG. 3 is a graph showing the results of evaluating the RNAi effect by quantitative RT-PCR when the siRNA of MOCS3 gene was transfected into the colon cancer cell line RKOE6.
FIG. 4 is a graph showing the results of evaluating the RNAi effect by measuring the number of living cells when siRNA of the MOCS3 gene was transfected into the colon cancer cell line RKOE6.
FIG. 5 is a photograph (phase contrast image) showing the results of verifying the RNAi effect with an optical microscope when the cell line CCD18Co derived from normal colon tissue was transfected with siRNA of the MOCS3 gene.
FIG. 6 is a graph showing the results of evaluating the RNAi effect by quantitative RT-PCR when the siRNA of the MOCS3 gene was transfected into the cell line CCD18Co derived from normal colon tissue.
FIG. 7 is a graph showing the results of verifying the RNAi effect by measuring the number of living cells when the cell line CCD18Co derived from normal colon tissue was transfected with siRNA of the MOCS3 gene.
FIG. 8 is a photograph showing the results of Northern hybridization performed using various normal organ tissues.
FIG. 9 is an optical micrograph (fluorescence image) of a part (6 cells) of cancer cells of a sample tissue derived from a colon cancer patient analyzed by the FISH method.
FIG. 10 is an optical micrograph (bright field image) showing the results of evaluation by immunohistochemical staining that the protein of the MOCS3 gene is expressed in cancer cells of the specimen tissue.
FIG. 11 is a graph showing the results of verifying the RNAi effect by measuring the number of viable cells when cervical cancer cell line HeLa cell line was transfected with siRNA of MOCS3 gene.
FIG. 12 is an optical micrograph (differential interference image) showing the result of photographing the experiment of FIG. 11 under a microscope according to time series and observing the dynamics in detail.
FIGS. 13A and 13B are graphs showing the results of (A) serum derived from a colon cancer patient and (B) serum derived from a healthy person analyzed by mass spectrometry, respectively.
14A to 14C show the correspondence between the peak shown in FIG. 13 and amino acids (or amino acid sequences) determined by MS / MS analysis.
FIG. 15-1 and FIG. 15-2 show a stomach (A: stomach), colon (B: colon), rectum (C: rectum), retina (expression) among the organs analyzed by immunohistochemical staining. D: epilon, lung (E, F, G: lung), ovary (I, J: ovary), prostate (L: prostate), lymph node (M: Lympnode), bone tissue (O: bone), and longitudinal Optics of samples from R (mediaastinum) and weakly expressed milk (H: breast), spleen (K: spleen), throat (P: throat), and adipose tissue (Q: fatty tissue) It is a microscope picture (bright field image).

本明細書中、「アンチセンス核酸」、または「アンチセンスポリヌクレオチド」とは、ある対象となるＤＮＡ領域の少なくとも一部に相補的なポリヌクレオチドを有し、そのポリヌクレオチドが当該領域の少なくとも一部とハイブリダイズすることができる核酸のことをいう。本発明のアンチセンス核酸は、ＲＮＡ、ＤＮＡ、あるいは修飾された核酸（ＲＮＡ、ＤＮＡ）である。本発明のアンチセンス核酸は、ＲＮＡ、ＤＮＡ、あるいは修飾された核酸（ＲＮＡ、ＤＮＡ）である。それらは二本鎖ＤＮＡ、一本鎖ＤＮＡ、二本鎖ＲＮＡ、一本鎖ＲＮＡ、さらにＤＮＡ：ＲＮＡハイブリッドであってもよい。修飾された核酸の具体例としては、核酸の硫黄誘導体やチオホスフェート誘導体、さらにはポリヌクレオチドアミドやオリゴヌクレオチドアミドの分解に抵抗性を有するものなどが挙げられるが、それらに限定されるものではない。
使用されるアンチセンス核酸は、適当なプロモーターの下流に連結され、好ましくは３’側に転写終結シグナルを含む配列が連結される。このようにして調製された核酸は、公知の方法を用いることで、所望の動物へ形質転換できる。アンチセンス核酸の配列は、形質転換される動物が持つ内在性遺伝子またはその一部と相補的な配列であることが好ましいが、遺伝子の発現を有効に抑制できる限りにおいて、完全に相補的でなくてもよい。
例えば、ＭＯＣＳ３遺伝子のｍＲＮＡの５’端近傍の非翻訳領域に相補的なアンチセンス配列を設計すれば、遺伝子の翻訳阻害に効果的である。コード領域もしくは３’側の非翻訳領域に相補的な配列も使用することができる。遺伝子の翻訳阻害に効果的なアンチセンス核酸は、標的遺伝子の転写産物に対して約７０％以上、好ましくは約８０％以上、より好ましくは約９０％以上、最も好ましくは約９５％以上の相補性を有する。
アンチセンス核酸を用いて標的遺伝子の発現を効果的に抑制するには、アンチセンス核酸の長さは少なくとも約１０塩基以上（例えば、１０〜４０個程度）、好ましくは約１５塩基以上であり、より好ましくは約１００塩基以上であり、さらに好ましくは約５００塩基以上である。アンチセンス核酸は公知の文献を参照して設計することができる（例えば、平島および井上、新生化学実験講座２ 核酸ＩＶ遺伝子の複製と発現、日本生化学会編、東京化学同人、１９９３、ｐ．３１９−３４７）、Ｊ．Ｋａｗａｋａｍｉ ｅｔ ａｌ．，Ｐｈａｒｍ Ｔｅｃｈ Ｊａｐａｎ．Ｖｏｌ．８，ｐ．２４７，１９９２；Ｖｏｌ．８，ｐ．３９５，１９９２；Ｓ．Ｔ．Ｃｒｏｏｋｅ ｅｔ ａｌ．，ｅｄ．，Ａｎｔｉｓｅｎｓｅ Ｒｅｓｅａｒｃｈ ａｎｄ Ａｐｐｌｉｃａｔｉｏｎｓ，ＣＲＣ Ｐｒｅｓｓ，１９９３など参照）。
また、本発明のがん治療剤においては、ＭＯＣＳ３遺伝子の転写産物を特異的に切断するリボザイム活性を有する核酸を有効成分として用いることができる。ここでいう「リボザイム活性」とは、ターゲットとする遺伝子の転写産物であるｍＲＮＡを部位特異的に切断する核酸のことをいう。リボザイムには、グループＩイントロン型やＲＮａｓｅＰに含まれるＭ１ ＲＮＡのように４００ヌクレオチド以上の大きさのものもあるが、ハンマーヘッド型やヘアピン型と呼ばれる４０ヌクレオチド程度の活性ドメインを有するものもある（タンパク質核酸酵素、１９９０、３５、ｐ．２１９１）。ハンマーヘッド型リボザイムについては、例えば、ＦＥＢＳ Ｌｅｔｔ，１９８８，２２８，ｐ．２２８；ＦＥＢＳ Ｌｅｔｔ，１９８８，２３９，ｐ．２８５；タンパク質核酸酵素，１９９０，３５，ｐ．２１９１；Ｎｕｃｌ Ａｃｉｄｓ Ｒｅｓ，１９８９，１７，ｐ．７０５９などを参照することができる。また、ヘアピン型リボザイムについては、例えば、Ｎａｔｕｒｅ，１９８６，３２３，ｐ．３４９；Ｎｕｃｌ Ａｃｉｄｓ Ｒｅｓ，１９９１，１９，ｐ．６７５１；菊池洋，化学と生物，１９９２，３０，ｐ．１１２などを参照することができる。このようなリボザイムを用いて本発明におけるＭＯＣＳ３遺伝子の転写産物を特異的に切断することで、該遺伝子の発現を阻害することができる。
さらに、本発明は、ＭＯＣＳ３遺伝子の転写活性を阻害する核酸以外の化合物を有効成分として用いることができる。そのような化合物は、例えば、ＭＯＣＳ３遺伝子の発現・転写に関与する因子に結合する化合物である。このような化合物は、天然物でも合成化合物でもよい。このような化合物は、後述のスクリーニング方法によって、取得することが可能である。
１．２ ＭＯＣＳ３タンパク質の活性阻害物質を含有するがん治療剤
本発明はまた、別の実施形態において、ＭＯＣＳ３タンパク質の活性阻害物質を含有するがん治療剤を提供する。
本明細書中、「ＭＯＣＳ３タンパク質の活性阻害物質」には、例えば、
（ａ）ＭＯＣＳ３タンパク質に結合する抗体、
（ｂ）ＭＯＣＳ３タンパク質に対してドミナントネガティブの性質を有するＭＯＣＳ３タンパク質変異体、あるいは
（ｃ）ＭＯＣＳ３タンパク質に結合する化合物（上記抗体および変異体を除く）
などが含まれる。
本明細書における「抗体」とはタンパク質の全長又は断片に反応する抗体を意味する。本発明の抗体の形態には、特に制限はなく、本発明のＭＯＣＳ３タンパク質に結合する限り、上記ポリクローナル抗体、モノクローナル抗体のほかに、ヒト抗体、遺伝子組み換えによるヒト型化抗体、さらにその抗体断片や抗体修飾物も含まれる。ＭＯＣＳ３タンパク質に結合する抗体（抗ＭＯＣＳ３抗体）は、当業者に公知の方法により調製することが可能である。なお、抗ＭＯＣＳ３抗体の詳細については後述する。
本明細書における「ＭＯＣＳ３タンパク質に対してドミナントネガティブの性質を有するＭＯＣＳ３タンパク質変異体」とは、それをコードする遺伝子を発現させることによって、内在性の野生型ＭＯＣＳ３タンパク質の活性を消失もしくは低下させる機能を有するタンパク質を指す（土田邦博著、遺伝子の活性阻害実験法 多比良和誠編、羊土社（２００１）２６−３２など参照）。
さらに、本発明においては、ＭＯＣＳ３タンパク質の活性を阻害し得る物質として、ＭＯＣＳ３タンパク質に結合する、上記抗体または変異体以外の化合物を有効成分として用いることができる。そのような化合物は、例えば、ＭＯＣＳ３タンパク質に結合し、その活性を阻害する化合物である。このような化合物は、天然物でも合成化合物でもよい。このような化合物は、後述のスクリーニング方法によって、取得することが可能である。
上記した本発明のＭＯＣＳ３タンパク質の活性を阻害し得る物質は、がん治療剤として使用することができる。
２．ＭＯＣＳ３タンパク質の活性もしくは発現を阻害する物質のスクリーニング方法
本発明は、がん抑制作用を有する候補化合物のスクリーニング方法をも提供する。
一つの好ましい態様は、ＭＯＣＳ３タンパク質と被検化合物との結合を指標とする方法である。通常、ＭＯＣＳ３タンパク質と結合する化合物は、ＭＯＣＳ３タンパク質の活性を阻害する効果を有することが期待される。ここで、該化合物は、ＭＯＣＳ３タンパク質の活性部位に結合することが好ましい。本方法においては、まず、ＭＯＣＳ３タンパク質と被検化合物とを接触させる。ＭＯＣＳ３タンパク質は、被検化合物との結合を検出するための指標に応じて、例えば、ＭＯＣＳ３タンパク質の精製された形態、細胞内または細胞外に発現した形態、あるいはアフィニティーカラムに結合した形態であり得る。この方法に用いる被検化合物は必要に応じて適宜標識して用いることができる。標識としては、例えば、放射標識、蛍光標識等を挙げることができる。
本方法においては、次いで、ＭＯＣＳ３タンパク質と被検化合物との結合を検出する。
本方法に用いる被検化合物としては、特に制限はない。例えば、天然化合物、有機化合物、無機化合物、タンパク質、ペプチドなどの単一化合物、並びに、化合物ライブラリー、遺伝子ライブラリーの発現産物、細胞抽出物、細胞培養上清、発酵微生物産生物、海洋生物抽出物、植物抽出物等が挙げられるが、これらに限定されない。
ＭＯＣＳ３タンパク質と被検化合物との結合は、例えば、ＭＯＣＳ３タンパク質に結合した被検化合物に付された標識によって検出することができる。また、細胞内または細胞外に発現しているＭＯＣＳ３タンパク質への被検化合物の結合により生じるＭＯＣＳ３タンパク質の活性の変化を指標として検出することもできる。タンパク質と被検化合物との結合活性は、公知の手法によって測定することができる（例えば、Ｎｉｔｒａｔｅ ｒｅｄｕｃｔａｓｅ活性やＳｕｌｆｕｒｔｒａｎｓｆｅｒａｓｅ 活性の測定（Ｍａｔｔｈｉｅｓ，Ａ．ｅｔ ａｌ．（２００４）ＰＮＡＳ １０１（１６），５９４６−５９５１参照））。
本方法においては、次いで、ＭＯＣＳ３タンパク質と結合し、その活性を阻害する被検化合物を選択する。
本方法により単離される化合物は、がん抑制作用を有することが期待され、がん治療剤として有用である。
本発明のスクリーニング方法の他の態様は、ＭＯＣＳ３遺伝子の発現を指標とする方法である。
本方法においては、まず、ＭＯＣＳ３遺伝子を発現する細胞に、被検化合物を接触させる。用いられる「細胞」の由来としては、ヒト、マウス、ネコ、イヌ、ウシ、ヒツジ、トリなど、ペット、家畜等に由来する細胞が挙げられるが、これら由来に制限されない。「ＭＯＣＳ３遺伝子を発現する細胞」としては、内因性のＭＯＣＳ３遺伝子を発現している細胞、または外因性のＭＯＣＳ３遺伝子が導入され、該遺伝子が発現している細胞を利用することができる。外因性のＭＯＣＳ３遺伝子が発現した細胞は、通常、それぞれＭＯＣＳ３遺伝子が挿入された発現ベクターを宿主細胞へ導入することにより作製することができる。該発現ベクターは、一般的な遺伝子工学技術によって作製することができる。
本方法に用いる被検化合物としては、特に制限はないが、例えば、天然化合物、有機化合物、無機化合物、タンパク質、ペプチドなどの単一化合物、並びに、化合物ライブラリー、遺伝子ライブラリーの発現産物、細胞抽出物、細胞培養上清、発酵微生物産生物、海洋生物抽出物、植物抽出物等が用いられる。
ＭＯＣＳ３遺伝子を発現する細胞への被検化合物の「接触」は、通常、それぞれＭＯＣＳ３遺伝子を発現する細胞の培養液に被検化合物を添加することによって行うが、この方法に限定されない。被検化合物がタンパク質等の場合には、該タンパク質を発現するＤＮＡベクターを、該細胞へ導入することにより、「接触」を行うことができる。
本方法においては、次いで、該ＭＯＣＳ３遺伝子の発現レベルを測定する。ここで「遺伝子の発現」には、転写および翻訳の双方が含まれる。遺伝子の発現レベルの測定は、当業者に公知の方法によって行うことができる。例えば、ＭＯＣＳ３遺伝子を発現する細胞からｍＲＮＡを常法に従って抽出し、このｍＲＮＡを鋳型としたノーザンハイブリダイゼーション法またはＲＴ−ＰＣＲ法を実施することによって該遺伝子の転写レベルの測定を行うことができる。あるいは、ＭＯＣＳ３遺伝子のプロモーター領域を常法に従って単離し、その下流に標識遺伝子（例えば、ルシフェラーゼ、ＧＦＰ、ガラクトシダーゼ等の発光、蛍光、発色などを指標に検出可能な遺伝子が挙げられるが、これらに限定されない）をつなげ、その標識遺伝子の活性を見ることによっても該遺伝子の転写レベルの測定を行うことができる。また、ＭＯＣＳ３遺伝子を発現する細胞からタンパク質画分を回収し、それぞれＭＯＣＳ３タンパク質の発現をＳＤＳ−ＰＡＧＥ等の電気泳動法で検出することにより、遺伝子の翻訳レベルの測定を行うこともできる。さらに、ＭＯＣＳ３タンパク質に対する抗体を用いて、ウエスタンブロッティング法を実施することにより該タンパク質の発現を検出することにより、遺伝子の翻訳レベルの測定を行うことも可能である。ＭＯＣＳ３タンパク質の検出に用いる抗体としては、検出可能な抗体であれば、特に制限はないが、例えばモノクローナル抗体、またはポリクローナル抗体の両方を利用することができる。
本方法においては、次いで、被検化合物を接触させない場合（コントロール）と比較して、該発現レベルを低下させる化合物を選択する。このようにして選択された化合物は、がん治療剤のための候補化合物となる。
３．抗ＭＯＣＳ３抗体及びこの抗体を含有する治療剤、複合体および組成物
本発明はまた、抗ＭＯＣＳ３抗体、この抗体を含有するがん治療剤などを提供する。本発明の１つの好ましい態様では、上記がん治療剤は、がんの標的化療法または標的化薬物送達のために使用される。
３．１ 抗ＭＯＣＳ３抗体
本明細書中、「抗ＭＯＣＳ３抗体」には、ＭＯＣＳ３タンパク質（その断片（部分ペプチド）もしくはその塩を含む）に特異的に結合する抗体が含まれる。本発明において使用する抗ＭＯＣＳ３抗体は、ポリクローナル抗体であってもよいし、モノクローナル抗体であってもよい。抗体のクラスは、特に限定されず、ＩｇＧ、ＩｇＭ、ＩｇＡ、ＩｇＤ、またはＩｇＥ等のいずれのアイソタイプを有する抗体をも包含する。好ましくは、ＩｇＧまたはＩｇＭであり、精製の容易性等を考慮すると、より好ましくはＩｇＧである。また、ここでいう「抗体」という用語は、任意の抗体断片または誘導体を含む意味で用いられ、例えば、Ｆａｂ、Ｆａｂ’_２、ＣＤＲ、ヒト化抗体、多機能抗体、単鎖抗体（ＳｃＦｖ）などを含む。本発明の抗体は、公知の方法で製造することができる。このような抗体の製造法は当該分野で周知である（例えばＨａｒｌｏｗ Ｅ．＆ Ｌａｎｅ Ｄ．，Ａｎｔｉｂｏｄｙ，Ｃｏｌｄ Ｓｐｒｉｎｇ Ｈａｒｂｏｒ Ｌａｂｏｒａｔｏｒｙ Ｐｒｅｓｓ（１９８８）を参照）。
（１）抗原の調製
本発明において、感作抗原として使用されるタンパク質は、通常、ＭＯＣＳ３タンパク質またはその塩である。上記ＭＯＣＳ３タンパク質には、その部分ペプチドも含まれ、これは、限定されることはないが、例えば、配列番号：２のアミノ酸配列の断片であって、例えば、２０個以上、４０個以上、６０個以上、８０個以上、１００個以上の、連続するアミノ酸配列部分を有する部分ペプチドである。これらの断片として、例えば、アミノ（Ｎ）末端断片やカルボキシ（Ｃ）末端断片が用いられる。本発明で用いられる部分ペプチドは、上記アミノ酸配列中の１または２個以上（好ましくは、１〜１０個程度、さらに好ましくは数個（１〜６個））のアミノ酸残基が欠失、置換、挿入及び／又は付加されたものであってもよい。ここで用いられるＭＯＣＳ３タンパク質またはその部分ペプチドの塩としては、例えば、無機酸（例えば、塩酸、硫酸）との塩、あるいは有機酸（例えば、酢酸、ギ酸、プロピオン酸）との塩などが用いられる。抗体取得の感作抗原として使用される本発明のＭＯＣＳ３タンパク質は、その由来となる動物種に制限されないが哺乳動物、例えばマウス、ヒト由来のタンパク質が好ましく、特にヒト由来のタンパク質が好ましい。
（２）ＭＯＣＳ３タンパク質に対するモノクローナル抗体の作製
（ｉ） 抗体産生細胞の採取
上記のようなＭＯＣＳ３タンパク質、その部分ペプチド又はその塩（本明細書中、抗体に関する説明では、これらをまとめて、「ＭＯＣＳ３タンパク質」という。）を抗原として、哺乳動物、例えばラット、マウス、ウサギなどに投与する。抗原の動物１匹当たりの投与量は、アジュバントを用いないときは０．１〜１００ｍｇであり、アジュバントを用いるときは１〜１００μｇである。アジュバントとしては、フロイント完全アジュバント（ＦＣＡ）、フロイント不完全アジュバント（ＦＩＡ）、水酸化アルミニウムアジュバント等が挙げられる。免疫は、主として静脈内、皮下又は腹腔内等に注入することにより行われる。また、免疫の間隔は特に限定されず、数日から数週間間隔、好ましくは２〜５週間間隔で、１〜１０回、好ましくは２〜５回免疫を行う。そして、最終の免疫日から１〜６０日後、好ましくは１〜１４日後に抗体産生細胞を採集する。抗体産生細胞としては、脾臓細胞、リンパ節細胞、末梢血細胞等が挙げられるが、脾臓細胞又は局所リンパ節細胞が好ましい。
（ｉｉ）細胞融合
ハイブリドーマを得るため、抗体産生細胞とミエローマ細胞との細胞融合を行う。抗体産生細胞と融合させるミエローマ細胞として、マウスなどの動物の一般に入手可能な株化細胞を使用することができる。使用する細胞株としては、薬剤選択性を有し、未融合の状態ではＨＡＴ選択培地（ヒポキサンチン、アミノプテリン、チミジンを含む）で生存できず、抗体産生細胞と融合した状態でのみ生存できる性質を有するものが好ましい。ミエローマ細胞としては、例えば Ｘ６３Ａｇ．８．６５３、ＮＳＩ／１−Ａｇ４−１、ＮＳ０／１などのマウスミエローマ細胞株、ＹＢ ２／０などのラットミエローマ細胞株が挙げられる。
次に、上記ミエローマ細胞と抗体産生細胞とを細胞融合させる。細胞融合は、血清を含まないＤＭＥＭ、ＲＰＭＩ−１６４０培地などの動物細胞培養用培地中で、１×１０^６〜１×１０^７個／ｍｌの抗体産生細胞と２×１０^５〜２×１０^６個／ｍｌのミエローマ細胞とを混合し（抗体産生細胞とミエローマ細胞との細胞比２：１〜３：１が好ましい）、細胞融合促進剤存在のもとで融合反応を行う。細胞融合促進剤として、平均分子量１０００〜６０００ダルトンのポリエチレングリコール等を使用することができる。また、電気刺激（例えばエレクトロポレーション）を利用した市販の細胞融合装置を用いて抗体産生細胞とミエローマ細胞とを融合させることもできる。
（ｉｉｉ） ハイブリドーマの選別及びクローニング
細胞融合処理後の細胞から目的とするハイブリドーマを選別する。その方法として、細胞懸濁液を例えばウシ胎児血清含有ＲＰＭＩ−１６４０培地などで適当に希釈後、マイクロタイタープレート上に３×１０^５個／ｗｅｌｌ程度まき、各ウエルに選択培地を加え、以後適当に選択培地を交換して培養を行う。その結果、選択培地で培養開始後、１４日前後から生育してくる細胞をハイブリドーマとして得ることができる。
次に、増殖してきたハイブリドーマの培養上清中に、ＭＯＣＳタンパク質に反応する抗体が存在するか否かをスクリーニングする。ハイブリドーマのスクリーニングは、通常の方法に従えばよく、特に限定されるものではない。例えば、ハイブリドーマとして生育したウエルに含まれる培養上清の一部を採集し、酵素免疫測定法、放射性免疫測定法等によってスクリーニングすることができる。融合細胞のクローニングは、限界希釈法等により行う。そして、最終的に、ＭＯＣＳタンパク質と反応するモノクローナル抗体を産生する細胞であるハイブリドーマを樹立する。
（ｉｖ）モノクローナル抗体の採取
上記のようにして得たハイブリドーマからモノクローナル抗体を採取する方法として、通常の細胞培養法又は腹水形成法等を採用することができる。細胞培養法においては、ハイブリドーマを１０％ウシ胎児血清含有ＲＰＭＩ−１６４０培地、ＭＥＭ培地又は無血清培地等の動物細胞培養培地中で、通常の培養条件（例えば３７℃、５％ ＣＯ_２濃度）で７〜１４日間培養し、その培養上清から抗体を取得する。腹水形成法の場合は、ミエローマ細胞由来の哺乳動物と同種系動物の腹腔内にハイブリドーマを約１×１０^７個投与し、ハイブリドーマを大量に増殖させる。そして、１〜２週間後に腹水を採取する。上記抗体の採取方法において抗体の精製が必要とされる場合は、硫安塩析法、イオン交換クロマトグラフィー、ゲル濾過、アフィニティークロマトグラフィーなどの公知の方法を適宜選択して、又はこれらを組み合わせることにより精製することができる。
（３）ＭＯＣＳ３タンパク質に対するポリクローナル抗体の作製
まず、上記した抗原を哺乳動物、例えばラット、マウス、ウサギなどに投与する。抗原の動物１匹当たりの投与量は、アジュバントを用いないときは０．１〜１００ｍｇであり、アジュバントを用いるときは１０〜１０００μｇである。アジュバントとしては、フロイント完全アジュバント（ＦＣＡ）、フロイント不完全アジュバント（ＦＩＡ）、水酸化アルミニウムアジュバント等が挙げられる。免疫は、主として静脈内、皮下又は腹腔内等に注入することにより行われる。また、免疫の間隔は特に限定されず、数日から数週間間隔、好ましくは２〜５週間間隔で、１〜１０回、好ましくは２〜５回免疫を行う。そして、最終の免疫日から６〜６０日後に、酵素免疫測定法（ＥＬＩＳＡ（ｅｎｚｕｍｅ−ｌｉｎｋｅｄ ｉｍｍｕｎｏｓｏｒｂｅｎｔ ａｓｓｙ）又は ＥＩＡ（ｅｎｚｙｍｅ ｉｍｍｕｎｏａｓｓａｙ））、放射性免疫測定法（ＲＩＡ；ｒａｄｉｏｉｍｍｕｎｏ ａｓｓａｙ）等で抗体価を測定し、最大の抗体価を示した日に採血し、抗血清を得る。
次いで、例えば、抗血清中のポリクローナル抗体を、ＭＯＣＳ３タンパク質で固定されたアフィニティーカラムにかけてＭＯＣＳ３タンパク質と反応する抗体（カラム吸着画分）を採取する。ＭＯＣＳ３タンパク質に対する抗血清中のポリクローナル抗体の反応性は、ＥＬＩＳＡ法などで測定することができる。
（４）抗体の断片など
ＦａｂまたはＦａｂ’_２断片は、従来の方法によるプロテアーゼ（例えば、ペプシンまたはパパイン）を用いた消化により作製することができる。ヒト化抗体は、例えばＲｉｅｃｈｍａｎｎら（Ｒｉｅｃｈｍａｎｎ Ｊ Ｍｏｌ Ｂｉｏｌ．Ｏｃｔ ５；２０３（３）：８２５−８，１９８８）、およびＪｏｎｅｓら（Ｊｏｎｅｓら Ｎａｔｕｒｅ ３２１：５２２−５２５，１９８６）に記載のような方法の１つにより調製することができる。
また、キメラ抗体は、例えば、「実験医学（臨時増刊号）、Ｖｏｌ．１．６，Ｎｏ．１０，１９８８」、特公平３−７３２８０号公報等を、ヒト化抗体は、例えば、「Ｎａｔｕｒｅ Ｇｅｎｅｔｉｃｓ，Ｖｏｌ．１５，ｐ．１４６−１５６，１９９７」、「Ｎａｔｕｒｅ Ｇｅｎｅｔｉｃｓ，Ｖｏｌ．７，ｐ．１３−２１，１９９４」、特表平４−５０４３６５号公報、国際出願公開ＷＯ９４・２５５８５号公報等、「日経サイエンス、６月号、第４０〜第５０頁、１９９５年」、「Ｎａｔｕｒｅ，Ｖｏｌ．３６８，ｐ．８５６−８５９，１９９４」、特表平６−５００２３３号公報等を参考にそれぞれ製造することができる。本発明のＭＯＣＳ３タンパク質に結合する抗体は、例えば、癌細胞の増殖もしくは転移の抑制等を目的とした使用が考えられる。得られた抗体を人体に投与する目的（抗体治療）で使用する場合には、免疫原性を低下させるため、ヒト抗体やヒト型抗体が好ましい。
抗体は、診断剤として用いる場合は、モニタリング等のための標識物質（例えば、放射性同位元素、蛍光物質など）で標識されていてもよい。必要に応じて、放射性物質、蛍光化合物などにより標識することができる。最も慣用の蛍光標識化合物の中には、フルオレセインイソチオシアネート、ローダミン、フィコエリトリンおよびフルオレスカミンがある。同様に、生体発光性化合物を用いて、抗体ＭＯＣＳ３抗体を標識することもできる。生体発光性タンパク質の存在は、蛍光の存在を検出することによって測定される。この標識目的に重要な生体発光性化合物は、ルシフェリン、ルシフェラーゼおよびイエクオリンである。
なお、本発明の抗体は、体液や組織などの被検体中に存在するＭＯＣＳ３タンパク質等を特異的に検出するために使用することができる。また、ＭＯＣＳ３タンパク質等を精製するために使用する抗体カラムの作製、精製時の各分画中のＭＯＣＳ３タンパク質等の検出、被検細胞内におけるＭＯＣＳ３タンパク質の挙動の分析などのために使用することができる、
３．２ 抗ＭＯＣＳ３抗体を含有する複合体など
また、本発明において使用する抗ＭＯＣＳ３抗体は、本発明の治療剤または診断剤において、それ自体が、抗原の活性を減弱させるような中和活性を有する薬剤（ａｇｅｎｔ）であり得るが、必要に応じて、治療効果を奏するための他の薬剤と組み合わせて用いることができる。したがって、本発明は、もう一つの態様において、がん（例えば、大腸がん）の標的化療法または標的化イメージング等に使用するための、抗ＭＯＣＳ３抗体と他の薬剤との複合体、そのような複合体を含有する組成物などをも提供する。このような態様によれば、本発明において使用する抗ＭＯＣＳ３抗体を用いて、治療効果を奏する他の薬剤または診断のための標識剤などを、ＭＯＣＳ３タンパク質を高発現する標的部位へ送達することができる。
本発明において用いられる「その他の薬剤」としては、例えば、放射性同位元素、治療タンパク質、または低分子の薬剤など、標的への遺伝子導入のためのウイルスベクターもしくは非ウイルスベクターなどが例示される。
本発明において、「放射性同位元素」の例としては、フッ素−１８、ヨウ素−１２５（^１２５Ｉ）、およびヨウ素−１３１などの放射性ハロゲン元素が挙げられる。これらの放射性ハロゲン元素も上述の放射性金属元素と同様に抗体やペプチドに標識して、放射性治治療剤あるいは放射性診断剤として広く利用し得る。例えば、^１２５Ｉまたは^１３１Ｉでのヨード化は、クロラミンＴ法等の公知の方法により、抗体または抗体断片に結合させることができる。さらに、診断用としてはテクネチウム−９９ｍ、インジウム−１１１およびガリウム−６７（^６７Ｇａ）など、また治療用としてはイットリウム−９０（^９０Ｙ）、レニウム−１８６（^１８６Ｒｅ）またはレニウム−１８８（^１８８Ｒｅ）などが使用され得る。放射性同位元素を用いて抗体に標識する場合には、通常、金属キレート剤が用いられる。金属キレート剤としては、ＥＤＴＡ、ＤＴＰＡ、ジアミノジチオ化合物、サイクラム、およびＤＯＴＡなどが知られている。これらのキレート剤は抗体に予め結合しておき、その後放射性金属で標識する場合と、放射性金属キレートを形成後、抗体に結合して標識する方法がある。
本発明において、「治療タンパク質」の例としては、免疫を担う細胞を活性化するサイトカインが好適であり、例えば、ヒトインターロイキン２、ヒト顆粒球−マクロファージ−コロニー刺激因子、ヒトマクロファージコロニー刺激因子、ヒトインターロイキン１２等が挙げられる。また、大腸がん細胞を直接殺傷するため、リシンやジフテリア毒素などの毒素を用いることができる。例えば、治療タンパク質との融合抗体については、抗体または抗体断片をコードするｃＤＮＡに治療タンパク質をコードするｃＤＮＡを連結させ、融合抗体をコードするＤＮＡを構築し、このＤＮＡを原核生物または真核生物用の発現ベクターに挿入し、この発現ベクターを原核生物または真核生物へ導入することにより発現させ、融合抗体を製造することができる。
「低分子の薬剤」は、本明細書中で「放射性同位元素」や「治療タンパク質」等以外の診断または治療用化合物を意味するものとして用いられる。「低分子の薬剤」の例としては、ナイトロジェン・マスタード、サイクロファスファミドなどのアルキル化剤、５−フルオロウラシル、メソトレキセートなどの代謝拮抗剤、ダウノマイシン、ブレオマイシン、マイトマイシンＣ，ダウノルビシン、ドキソルビシンなどの抗生物質、ビンクリスチン、ビンブラスチン、ビンデシンのような植物アルカロイド、タモキシフェン、デキサメタソンなどのホルモン剤等の抗癌剤（臨床腫瘍学（日本臨床腫瘍研究会編 １９９６年 癌と化学療法社））、またはハイドロコーチゾン、プレドニゾンなどのステロイド剤、アスピリン、インドメタシンなどの非ステロイド剤、金チオマレート、ペニシラミンなどの免疫調節剤、サイクロフォスファミド、アザチオプリンなどの免疫抑制剤、マレイン酸クロルフェニラミン、クレマシチンのような抗ヒスタミン剤等の抗炎症剤（炎症と抗炎症療法 昭和５７年 医歯薬出版株式会社）などがあげられる。例えば、ダウノマイシンと抗体を結合させる方法としては、グルタールアルデヒドを介してダウノマイシンと抗体のアミノ基間を結合させる方法、水溶性カルボジイミドを介してダウノマイシンのアミノ基と抗体のカルボキシル基を結合させる方法等があげられる。
「ウイルスベクター」の例としては、本発明の抗ＭＯＣＳ３抗体に結合し得るように改変されたウイルスベクターが使用し得る（例えば、アデノウイルスベクター（Ｗａｎｇ，Ｐ．，ｅｔ ａｌ．（１９９５）Ｓｏｍａｔｉｃ Ｃｅｌｌ ａｎｄ Ｍｏｌｅｃ．Ｇｅｎｅｔ．２１，４２９−４４１）、レトロウイルスベクター（Ｎａｖｉａｕｘ Ｒ．Ｋ．，ｅｔ ａｌ．（１９９６）Ｊ．Ｖｉｒｏｌ ７０，５７０１−５７０５）、レンチウイルスベクター（Ｎａｌｄｉｎｉ，Ｌ．（１９９８）Ｃｕｒｒ．Ｏｐｉｎ．Ｂｉｏｔｅｃｈｎｏｌ．９，４５７−４６３）などが挙げられる）。このようなウイルスベクターには、細胞増殖関連遺伝子、アポトーシス関連遺伝子、免疫制御遺伝子等の、標的部位（例えば、大腸がん）において、例えば、癌細胞のアポトーシスを誘導するなどの治療効果を奏する遺伝子（治療遺伝子）が組み込まれる。抗ＭＯＣＳ３抗体に結合するウイルスベクターは、抗ＭＯＣＳ３抗体と共に遺伝子治療を必要とする患者に投与された場合、抗ＭＯＣＳ３抗体が認識する抗原（すなわち、ＭＯＣＳ３）が存在する部位に標的化することができる。
抗ＭＯＣＳ３抗体と上記他の薬剤とは、化学的または遺伝子工学的に結合され得る。ここで、「化学的な結合」には、イオン結合、水素結合、共有結合、分子間力による結合、疎水性相互作用による結合などが含まれるものとし、「遺伝子工学的な結合」には、例えば、抗体と治療タンパク質とからなる融合タンパク質を遺伝子組換えなどの技術を用いて作製した場合の、抗体と治療タンパク質との間の結合様式などが含まれるものとする。
４．製剤化および製剤の投与方法
本発明のＭＯＣＳ３遺伝子の発現阻害物質を含有するがん治療剤、ＭＯＣＳ３タンパク質の活性阻害物質を含有するがん治療剤、本発明の抗ＭＯＣＳ３抗体を含有する治療剤、または本発明において使用する抗ＭＯＣＳ３抗体が、放射性同位元素、治療タンパク質、低分子の薬剤、および治療遺伝子を担持したウイルスベクターもしくは非ウイルスベクターのうちのいずれか、またはこれらの任意の組み合わせと化学的または遺伝子工学的に結合されている治療剤は、公知の手法に基づいて製剤化することができる。
本発明の治療剤の製剤化にあたっては、常法に従い、必要に応じて薬学的に許容される担体を添加することができる。例えば、界面活性剤、賦形剤、着色料、着香料、保存料、安定剤、緩衝剤、懸濁剤、等張化剤、結合剤、崩壊剤、滑沢剤、流動性促進剤、矯味剤等が挙げられるが、これらに制限されず、その他常用の担体を適宜使用することができる。具体的には、軽質無水ケイ酸、乳糖、結晶セルロース、マンニトール、デンプン、カルメロースカルシウム、カルメロースナトリウム、ヒドロキシプロピルセルロース、ヒドロキシプロピルメチルセルロース、ポリビニルアセタールジエチルアミノアセテート、ポリビニルピロリドン、ゼラチン、中鎖脂肪酸トリグリセライド、ポリオキシエチレン硬化ヒマシ油６０、白糖、カルボキシメチルセルロース、コーンスターチ、無機塩類等を挙げることができる。
本発明の治療剤の剤型の種類としては、例えば、経口剤として錠剤、粉末剤、丸剤、散剤、顆粒剤、細粒剤、軟・硬カプセル剤、フィルムコーティング剤、ペレット剤、舌下剤、ペースト剤等、非経口剤として注射剤、坐剤、経皮剤、軟膏剤、硬膏剤、外用液剤等が挙げられ、当業者においては投与経路や投与対象等に応じた最適の剤型を選ぶことができる。有効成分としてのＭＯＣＳ３タンパク質の活性（またはＭＯＣＳ３遺伝子の発現）阻害物質は、製剤中０．１から９９．９重量％含有することができる。
本発明の薬剤の有効成分の投与量は、投与対象、対象臓器、症状、投与方法などにより差はあるが、経口投与の場合、一般的に例えば、患者（６０ｋｇとして）に対して一日につき約０．１ｍｇ〜１，０００ｍｇ、好ましくは約１．０〜１００ｍｇ、より好ましくは約１．０〜５０ｍｇである。非経口的に投与する場合は、その一回投与量は投与対象、対象臓器、症状、投与方法などによっても異なるが、例えば、注射剤の形では通常例えば、患者（６０ｋｇに対して）、一日につき約０．０１から３０ｍｇ程度、好ましくは約０．１から２０ｍｇ程度、より好ましくは約０．１〜１０ｍｇ程度を静脈注射により投与するのが好都合である。しかしながら、最終的には、剤型の種類、投与方法、患者の年齢や体重、患者の症状等を考慮して、医師または獣医師の判断により適宜決定することができる。
このようにして得られる製剤は、例えば、ヒトやその他の哺乳動物（例えば、ラット、ウサギ、ヒツジ、ブタ、ウシ、ネコ、イヌ、サルなど）に対して投与することができる。ヒト以外の動物の場合も、上記の６０ｋｇ当たりに換算した量を投与することができる。
本発明の治療剤は、がん（例えば、大腸がん、胃がん、肺がん、乳がん、前立腺がん、食道がん、肝臓がん、胆道がん、脾臓がん、腎がん、膀胱がん、子宮がん（例：子宮頸がん、子宮体がん）、精巣がん、甲状腺がん、膵臓がん、卵巣がん、脳腫瘍、血液腫瘍など）の予防・治療、好ましくは、大腸がんの予防・治療に用いられる。
本発明の薬剤は、ＭＯＣＳ３タンパク質の活性阻害物質またはＭＯＣＳ３遺伝子の発現阻害物質を有効成分として含有しているため、抗癌剤、癌転移阻害剤、癌細胞のアポトーシス誘導剤等として使用し得る。対象となる細胞、組織、臓器、または癌の種類は特定のものに限定されない。また、本発明の薬剤は、ＭＯＣＳ３タンパク質の活性阻害物質およびＭＯＣＳ３遺伝子の発現阻害物質の両方を含んでいても良い。
本発明の治療剤において、アンチセンス核酸を用いる場合、該アンチセンス核酸を単独あるいはレトロウイルスベクター、アデノウイルスベクター、アデノウイルスアソシエーテッドウイルスベクターなどの適当なベクターに挿入した後、公知の手段に従って投与することができる。アンチセンス核酸は、単独で、あるいは生理学的に認められる担体とともに製剤化し、遺伝子銃やハイドロゲルカテーテルのようなカテーテルによって投与することができる。
また、本発明において組換えアデノウイルス粒子のようなウイルスベクターと抗ＭＯＣＳ３抗体との組み合わせを癌治療のために使用する場合は、これら単独で使用してもよいが、一般には製薬的に許容できる担体と共に使用される。そのような担体としては、既に上記したような担体、ならびに水、生理食塩水、グルコース、ヒトアルブミン等の水性等張溶液が好ましい。更に、製薬的に通常使用される添加剤、保存剤、防腐剤、衡量等を添加することもできる。そのように調製した医薬組成物は、治療すべき疾病に依存して適切な投与形態、投与経路によって投与することができる。投与形態としては、例えば、乳剤、シロップ剤、カプセル、錠剤、顆粒剤、注射剤、軟膏等が挙げられる。本発明の抗ＭＯＣＳ３抗体−ウイルスベクター粒子またはこれを含む医薬組成物を治療のために投与する場合は、通常成人一人当たり１回に１０^３〜１０^１５個のウイルス粒子を投与するのが好ましいが、疾病の状態や標的細胞・組織の性質によって変更してよい。投与回数は、１日１回〜数回でよく、投与期間は１日〜数ヶ月以上にわたってもよく、１〜数回の投入を１セットとして、長期にわたって断続的に多数セットを投与してもよい。また、本発明において使用されるウイルスベクター粒子またはウイルスベクター核酸分子は、特定の細胞および／または組織の検出、または疾病状態の診断に使用することができる。例えば、ウイルスベクターの核酸分子に検出可能なマーカー遺伝子を組込み、これを適切な宿主細胞にトランスフェクションして得られたウイルスベクター粒子は、抗ＭＯＣＳ３抗体と組み合わせて腫瘍細胞を検出診断するために使用することができる。あるいは、抗ＭＯＣＳ３抗体に検出可能な標識を結合させて腫瘍細胞を検出診断するために使用することができる。
５．がんの診断剤及び診断方法
本発明はまた、がんの診断剤を提供する。１つの好ましい態様において、本発明のがんの診断剤は、（ａ）ＭＯＣＳ３タンパク質に対する抗体、又は（ｂ）ＭＯＣＳ３遺伝子またはその一部の塩基配列にストリンジェントなハイブリダイゼーション条件下でハイブリダイズ可能な塩基配列からなるポリヌクレオチドを含有する。
５．１ 抗体ＭＯＣＳ３抗体を用いる診断剤及び診断方法
ＭＯＣＳ３タンパク質に対する抗体は、ＭＯＣＳ３タンパク質等を特異的に認識することができるので、被検液中のＭＯＣＳ３タンパク質を定量することができる。具体的には、本発明の抗ＭＯＣＳ３抗体を用いる診断方法は、例えば、（ａ）被験者由来の生体試料と、ＭＯＣＳ３タンパク質に対する抗体とを接触させる工程、および（ｂ）前記試料中での前記抗体と、ＭＯＣＳ３タンパク質もしくはその部分ペプチドまたはその塩との結合を検出および／または定量する工程を包含する。好ましくは、上記検出および／または定量する工程において、標識された抗ＭＯＣＳ３抗体を用いて、ＭＯＣＳ３タンパク質またはその断片と抗ＭＯＣＳ３抗体との結合が検出および／または定量される。
本明細書中、「被験者由来の生体試料」は、被験者由来の組織、細胞、または体液（例えば、血液（全血、血漿、血清等を含む）、尿、リンパ液、唾液、汗、精液等）を含む。また、「被験者」は、通常、がん検診を受ける、または受けることが望まれるヒト被験体であり、がんに罹患しているか、または罹患していると疑われるヒト被験体等が含まれる。このようながんの例としては、大腸がん、胃がん、肺がん、乳がん、前立腺がん、食道がん、肝臓がん、胆道がん、脾臓がん、腎がん、膀胱がん、子宮がん（例：子宮頸がん、子宮体がん）、精巣がん、甲状腺がん、膵臓がん、卵巣がん、脳腫瘍、血液腫瘍などが含まれるが、とりわけ、大腸がんが好ましい。
上記のような被験者由来の生体試料におけるＭＯＣＳ３の発現を検出するための免疫測定は、がん（例えば、大腸がん）を有すると疑われるか、がんの危険性を有する被験体から採取した生体試料を、特異的抗原−抗体結合を生じさせる条件下で抗ＭＯＣＳ３抗体と接触させ、次いで、抗体による免疫特異的結合量を測定することを包含する。このような抗体の結合を使用して、ＭＯＣＳ３タンパク質の存在および／または増大した発現が検出される。この場合、増大したＭＯＣＳ３タンパク質発現の検出が疾病状態の指標となる。必要に応じて、生体試料中のＭＯＣＳ３タンパク質のレベルを、がんを有しない健常者のレベルと比較してもよい。
上記免疫測定法の１つの態様では、例えば、血清試料などの生体試料を、試料中に存在する全部のタンパク質を固定する目的で、ニトロセルロースなどの固相支持体または担体と接触させる。次いで、この支持体を緩衝液で洗浄し、続いて検出可能に標識した抗ＭＯＣＳ３抗体により処理する。次いで、この固相支持体を緩衝液で２回洗浄し、未結合抗体を除去する。固相支持体上の結合した抗体の量を、周知の方法に従って測定する。各測定に適する検出条件は、慣用的な試験方法を使用して当業者により適宜決定され得る。
抗ＭＯＣＳ３抗体を検出可能に標識する方法の１つにおいて、当該抗体を、酵素、例えば、酵素イムノアッセイ（ＥＩＡ）に使用されるもののような酵素に結合させる［Ｖｏｉｌｅｒ，Ａ．による「酵素標識した免疫吸着アッセイ」（“Ｔｈｅ Ｅｎｚｙｍｅ Ｌｉｎｋｅｄ Ｉｍｍｕｎｏｓｏｒｂｅｎｔ Ａｓｓａｙ）（ＥＬＩＳＡ），１９７８，Ｄｉａｇｎｏｓｔｉｃ Ｈｏｒｉｚｏｎｓ，２：１〜７，Ｍｉｃｒｏｂｉｏｌｏｇｉｃａｌ Ａｓｓｏｃｉａｔｅｓ Ｑｕａｒｔｅｒｌｙ Ｐｕｂｌｉｃａｔｉｏｎ，Ｗａｌｋｅｒｓｖｉｌｌｅ．ＭＤ；Ｖｏｉｌｅｒ，Ａ．によるＪ．Ｃｌｉｎ．Ｐａｔｈｏｌ．，３１：５０７〜５２０，１９７８：Ｂｕｔｉｅｒ，Ｊ．Ｅ．によるＭｅｔｈ．Ｅｎｚｙｍｏｌ．，７３：４８２〜５２３，１９８１］。抗体に結合する酵素を、例えば分光光度測定により、可視手段による蛍光測定により検出することができる化学分子が生成されるような方法で、適当な基質、好ましくは色素原性基質と反応させる。抗体に検出可能な標識を付けるために使用することができる酵素は、ペルオキシダーゼおよびアルカリ性ホスファターゼを包含するが、これらに限定されない。この検出はまた、酵素に対する色素原性基質を用いる比色法により達成することができる。
その他の本発明において使用し得る方法としては、ラジオイムノアッセイ（ＲＩＡ）、サンドイッチ免疫測定法、イムノメトリック法、ネフロメトリー、蛍光免疫測定法（ＦＩＡ）、時間分解蛍光免疫測定法（ＴＲＦＩＡ）、酵素免疫測定法（ＥＩＡ）、発光免疫測定法（ＬＩＡ）、電気化学発光免疫測定法（ＥＣＬＩＡ）、ラテックス凝集法、免疫沈降アッセイ、沈降素反応法、ゲル拡散沈降素反応法、免疫拡散検定法、凝集素検定法、補体結合検定法、免疫放射分析検定法、蛍光免疫検定法、およびプロテインＡ免疫検定法からなる群から選択される免疫測定法などが挙げられる（ＷＯ００／１４２２７号公報第３９頁第２５行〜第４２頁第８行、ＥＰ１１１１０４７Ａ２号公報段落［０１１５］第１９頁第３５行〜第２０頁第４７行など参照）。
以上のように、本発明の抗体を用いる、生体内でのＭＯＣＳ３タンパク質の定量法を利用することにより、ＭＯＣＳ３タンパク質の機能不全に関連する各種疾患の診断をすることができる。例えば、ＭＯＣＳ３タンパク質の濃度増加が検出された場合は、例えば、ＭＯＣＳ３タンパク質の過剰発現に起因する疾患（例えば、がん（例：大腸がん））である可能性が高いまたは将来罹患する可能性が高いと診断することができる。
なお、本発明の抗ＭＯＣＳ３抗体は、ｉｎ ｖｉｖｏでの診断に用いることもできる。ここで使用し得る抗体調製物の調製および使用方法は当該分野でよく知られている。例えば、抗体−キレート剤について、Ｎｕｃｌ．Ｍｅｄ．Ｂｉｏｌ．１９９０ １７：２４７−２５４に記載されている。また、磁気共鳴イメージングで用いる標識としての常磁性イオンを有する抗体については、例えば、Ｍａｇｎｅｔｉｃ Ｒｅｓｏｎａｎｃｅ ｉｎ Ｍｅｄｉｃｉｎｅ １９９１ ２２：３３９−３４２に記載されている。
５．２ ポリヌクレオチド（例えば、ＤＮＡ）プローブを用いる診断剤及び診断方法
本発明の診断方法においては、ＭＯＣＳ３遺伝子の塩基配列に基づいて設計されるプローブ又はプライマーを用いることができる。具体的には、そのような診断方法は、例えば、（ａ）被験者由来の生体試料と、ＭＯＣＳ３遺伝子またはその断片の塩基配列にストリンジェントなハイブリダイゼーション条件下でハイブリダイズ可能な塩基配列からなるポリヌクレオチド（プローブ）とを接触させる工程、および（ｂ）前記試料中での前記ポリヌクレオチドと、ＭＯＣＳ３遺伝子またはその断片とのハイブリダイゼーションを検出および／または定量する工程を包含する。
上記本発明の方法では、被験者由来の生体試料中のＭＯＣＳ３遺伝子のＤＮＡ（またはその遺伝子断片）を、上記プローブを使用して検出および／または定量する。プローブとして用いる塩基配列の長さは、例えば、１２塩基以上、１５塩基以上、１８塩基以上、２１塩基以上、２４塩基以上、２７塩基以上、３０塩基以上、またはさらに長い長さのポリヌクレオチド断片であり得る。ハイブリダイゼーションには、上記した低、中又は高ストリンジェントな条件を使用し得る。なお、本明細書中、「ＭＯＣＳ３遺伝子またはその断片の塩基配列にストリンジェントなハイブリダイゼーション条件下でハイブリダイズ可能な塩基配列」には、ＭＯＣＳ３遺伝子またはその断片の塩基配列に相補的な塩基配列（アンチセンスポリヌクレオチド）も含まれるものとする。プローブおよび核酸のハイブリダイゼーションの方法は当業者に知られており、例えば国際公開公報第８９／０６６９８号、ＥＰ−Ａ０２００３６２、米国特許第２，９１５，０８２号、ＥＰ−Ａ００６３８７９、ＥＰ−Ａ０１７３２５１、ＥＰ−Ａ０１２８０１８に記載されている。
本発明の診断方法においては、ＭＯＣＳ３遺伝子に対する特異的ポリヌクレオチドプローブまたはプライマーを用いて、公知の手法を用いて標的配列を検出または定量することができる。そのような公知の手法として、例えば、サザンハイブリダイゼーション、ノーザンハイブリダイゼーション、ＲＴ−ＰＣＲ法、ＰＣＲ−ＳＳＣＰ法（Ｇｅｎｏｍｉｃｓ，第５巻，８７４〜８７９頁（１９８９年））、Ｐｒｏｃｅｅｄｉｎｇｓ ｏｆ ｔｈｅ Ｎａｔｉｏｎａｌ Ａｃａｄｅｍｙ ｏｆ Ｓｃｉｅｎｃｅｓ ｏｆ ｔｈｅ Ｕｎｉｔｅｄ Ｓｔａｔｅｓ ｏｆ Ａｍｅｒｉｃａ，第８６巻，２７６６〜２７７０頁（１９８９年））、ＦＩＳＨ法、ＤＮＡチップあるいはアレイＣＧＨ（Ｃｏｍｐａｒａｔｉｖｅ Ｇｅｎｏｍｉｃ Ｈｙｂｒｉｄｉｚａｔｉｏｎ）法などを用いることができる。定量的な検出は、定量ＲＴ−ＰＣＲによって実施可能である。 アレイＣＧＨ法は、染色体ＣＧＨ法（Ｋａｌｌｉｏｎｉｅｍｉ，Ａ．ｅｔ ａｌ．（１９９２）Ｓｃｉｅｎｃｅ ２５８，８１８−８２１）を応用した方法で、スライド上に染色体領域をカバーするゲノムＤＮＡ断片（ＢＡＣ，ＰＡＣ，ＹＡＣなど）を高密度にスポットしたＤＮＡチップを用いて、別々の色素で標識したがん由来ＤＮＡと正常ＤＮＡを、スライド上のゲノムＤＮＡ断片に対して同時にハイブリダイゼーションを行い、その結合状態を検出することにより、がんにおけるＤＮＡコピー数異常を高解像度に検出する方法である（Ｐｉｎｋｅｌ，Ｄ．ｅｔ ａｌ．（１９９８）Ｎａｔ．Ｇｅｎｅｔ．２０，２０７−２１１）。
なお、本発明においては、ＭＣＯＳ３遺伝子の発現が上方制御されるか否かを検出するために、細胞のＭＣＯＳ３のｍＲＮＡレベルを標準遺伝子（ハウスキーピング遺伝子（例えば、Ｓｈａｐｅｒ，Ｎ．Ｌ．ら、Ｊ．Ｍａｍｍａｒｙ Ｇｌａｎｄ Ｂｉｏｌ．Ｎｅｏｐｌａｓｉａ ３（１９９８）３１５−３２４；Ｗｕ，Ｙ．Ｙ．およびＲｅｅｓ，Ｊ．Ｌ．、Ａｃｔａ Ｄｅｒｍ．Ｖｅｎｅｒｅｏｌ．８０（２０００）２−３）のｍＲＮＡレベルと、好ましくはＲＴ−ＰＣＲによって比較することもできる。
上記のような手法によって標的配列（ＤＮＡ、ｍＲＮＡなど）を検出・定量し、ＭＯＣＳ３遺伝子の発現過多が確認された場合は、例えば、ＭＯＣＳ３の過剰発現に起因する疾患（例えば、がん（例：大腸がん、子宮頸がん））である可能性が高い、あるいは将来罹患する可能性が高いと診断することができる。
５．３診断用キット
本発明はまた、抗ＭＯＣＳ３抗体を含有する、被験者の体液試料中のＭＯＣＳ３タンパク質またはその断片をがんマーカーとして検出および／または定量するためのキットを提供する。さらに、ＭＯＣＳ３遺伝子またはその一部の塩基配列にストリンジェントなハイブリダイゼーション条件下でハイブリダイズ可能な塩基配列を含有する、被験者由来の生体試料中のＭＯＣＳ３遺伝子またはその断片をがんマーカーとして検出および／または定量するためのキットをも提供する。これらのキットは、上述の免疫学的手法またはハイブリダイゼーション法等により、がんマーカーを検出するために用いられる。このようながんとしては、例えば、大腸がん、胃がん、肺がん、乳がん、前立腺がん、食道がん、肝臓がん、胆道がん、脾臓がん、腎がん、膀胱がん、子宮がん（例：子宮頸がん、子宮体がん）、精巣がん、甲状腺がん、膵臓がん、卵巣がん、脳腫瘍、血液腫瘍などが含まれるが、とりわけ、大腸がんが好ましい。
本明細書中、「がんマーカー」とは、被験者の体液（例えば、血液、尿、リンパ液、唾液、汗、精液等）または細胞もしくは組織中における、正常組織に由来していないか、あるいはがん細胞または組織において選択的に発現の亢進している分子のことをいい、被験者の体液または細胞もしくは組織中における当該分子の存在ががんの存在を示すかまたは示唆するものをいう。
上記第一の態様のキットは、被験者からの体液試料中のＭＯＣＳ３抗原（ＭＯＣＳ３タンパク質およびその部分ペプチドを含む）を検出および／または定量する成分を含有する。例えば、ＭＯＣＳ３タンパク質がＥＬＩＳＡで検出および／または定量される場合、このような成分は、例えば、組織切片、または血液や尿のような体液試料中のＭＯＣＳ３のレベルを検出および／または定量するために使用され得る。このような抗体は放射能、蛍光、比色、または酵素標識で標識されていてもよい。本発明のキットは、標識された二次抗体を含有していてもよい。
上記第二の態様のキットは、ＭＯＣＳ３遺伝子またはその一部の塩基配列にストリンジェントなハイブリダイゼーション条件下でハイブリダイズ可能な塩基配列からなるポリヌクレオチドを含有する。例えば、本発明のキットは、ＤＮＡチップ上に固定された上記ポリヌクレオチドを含有し得る。
本発明のキットは、抗ＭＯＣＳ３抗体、ＭＯＣＳ３遺伝子またはその一部の塩基配列にストリンジェントなハイブリダイゼーション条件下でハイブリダイズ可能な塩基配列等の他に、代表的には、容器およびラベルを含んでいる。容器上のまたは容器に伴うラベルには、薬剤が大腸がんマーカーの検出に使用されることが示されていてもよい。また、他のアイテム、例えば、使用説明書、標識二次抗体等がさらに含まれていてもよい。
以下、本発明を実施例を用いてより具体的に説明するが、本発明の範囲は、これらの実施例によって限定されない。   The present inventors verified the amplified gene by the array CGH method using a specimen derived from a colon cancer patient, and identified a gene amplification region specific to the colon cancer. Of the regions where amplification occurs frequently in the specimen, it was found that the human MOCS3 (Molybdenum factor synthesis 3) gene is frequent in specimens derived from colon cancer patients.
  The human MOCS3 gene found by the present inventors is involved in the synthesis system of oxidoreductases including molybdenum.
  Molybdenum is a trace element contained in many foods such as legumes, dairy products, and meat, and is known to play an important role in vivo. Molybdenum is combined with Polybdotterin (MTP) to become a Mollendenum factor (Moco). Moco is essential for the activity of three enzymes: xanthine oxidase (XO), aldehyde oxidase (AO), and sulfite oxidase (SO). XO is involved in the metabolism of purine derivatives, AO catalyzes the oxidation of aldehydes to carboxylic acids, and SO is an enzyme that oxidizes sulfites required for metabolism of sulfur-containing amino acids to sulfuric acid.
  Molybdenum deficiency has been reported in patients receiving long-term complete parenteral nutrition with clinical signs such as increased heartbeat, headache, mental disorders, and coma. Symptoms caused by this molybdenum deficiency include very low uric acid levels in serum and urine due to low XO activity, and low inorganic sulfuric acid levels in urine due to low SO activity. Molybdenum cofactor deficiency due to congenital anomalies showing symptoms such as severe brain damage and ocular vitreous dislocation is known (Sardesai, VM (1993) Nutr Clin Pract. 8 (6), 277-). 81).
  Molybdenum cofactor deficiency has been reported to involve two mutations of Polybdenum factor synthesis 1 (MOCS1) and 2 (MOCS2) (Reiss, J. et al. (1998) Am. J. Hum. Genet. 103, 639-644; Reiss, J. et al. (1999) Am. J. Hum. Genet. 64, 706-711).
  MOCS3 identified as a human homologous gene of the MoeB gene (Lake, MW et al. (2001) Nature 414, 325-329) of MTP synthesis-related enzyme of E. coli is homologous to MoeB on the N-terminal side. However, the C-terminal side is homologous to Rhodane (thiosulfate: cyanide sulfurtransferase, EC 2.8.1.1) (Mendel, RR & Schwarz, G. (2002) Met. Ions Biol). Syst. 39, 317-368).
  MOCS3 activates MOCS2 by transferring sulfur to MOCS2 in the MTP synthesis system. Activated MOCS2 converts PrecursorZ synthesized from GTP by MOCS1 into MTP (Matties, A. et al. (2004) PNAS 101 (16), 5946-5951; Matties, A. et al. (2005). Biochem. 44, 7912-7920). MTP synthesized in this way is combined with molybdenum to become Moco. Moco is essential for the activity of three enzymes: xanthine oxidase (XO), aldehyde oxidase (AO), and sulfite oxidase (SO).
  The present inventors have also confirmed that cancer cell growth can be suppressed by suppressing the expression of the MOCS3 gene by RNAi (RNA interference). Therefore, cancer can be treated by suppressing the expression of the MOCS3 gene. It is also possible to diagnose cancer by measuring the expression level of the MOCS3 gene.
  Hereinafter, the cancer therapeutic agent, screening method, diagnostic agent and the like of the present invention will be described in detail.
1. Drugs that suppress cancer
  First, the present invention provides (1) a cancer therapeutic agent containing a MOCS3 gene expression inhibitor as an active ingredient, and (2) a cancer therapeutic agent containing a MOCS3 protein activity inhibitor as an active ingredient.
  In the present specification, “MOCS3 gene” refers to Accession No. in the NCBI nucleotide database. : Means the human MOCS3 gene (SEQ ID NO: 1) consisting of 2458 bases registered in NM_014484, but is not limited thereto, for example, substitution, deletion, addition of one or more bases in the base sequence of the gene Or a gene comprising a polynucleotide comprising a nucleotide sequence that can hybridize under stringent hybridization conditions to the nucleotide sequence of the gene or a complementary sequence thereof, such as a variant that is altered by having an insertion, etc. It shall be included in the “MOCS3 gene” as used herein.
  Hybridization can be performed according to a known method or a method analogous thereto, for example, the method described in Molecular Cloning (Edition, J. Sambrook et al., Cold Spring Harbor Lab. Press. 2001). Moreover, when using a commercially available library, it can carry out according to the method as described in an attached instruction manual. Here, the “stringent conditions” may be any of low stringent conditions, medium stringent conditions, and high stringent conditions. “Low stringent conditions” are, for example, conditions of 5 × SSC, 5 × Denhardt's solution, 0.5% SDS, 50% formamide, and 32 ° C. The “medium stringent conditions” are, for example, conditions of 5 × SSC, 5 × Denhardt's solution, 0.5% SDS, 50% formamide, and 42 ° C. “High stringent conditions” are, for example, conditions of 5 × SSC, 5 × Denhardt's solution, 0.5% SDS, 50% formamide, 50 ° C. Under these conditions, it can be expected that DNA having higher homology can be efficiently obtained as the temperature is increased. However, multiple factors such as temperature, probe concentration, probe length, ionic strength, time, and salt concentration can be considered as factors that affect hybridization stringency. Those skilled in the art will select these factors as appropriate. It is possible to achieve similar stringency.
  As a hybridizable polynucleotide, when calculated using homology search software such as FASTA and BLAST using default parameters, the base sequence of SEQ ID NO: 1, for example, 70% or more, 75% or more, 80 % Or more, 85% or more, 90% or more, 91% or more, 92% or more, 93% or more, 94% or more, 95% or more, 96% or more, 97% or more, 98% or more, 99% or more The polynucleotide which has can be mention | raise | lifted.
  In the present specification, “inhibition of gene expression” means any event in a series of events from gene to protein production (for example, including transcription (mRNA production) and translation (protein production)). By inhibiting it is meant inhibiting the production of the protein encoded by the gene.
  In the present specification, “MOCS3 protein” refers to Accession No. in the NCBI protein database. : A human MOCS3 protein (SEQ ID NO: 2) consisting of 460 amino acid residues registered in NP — 055299 and an activity substantially the same as this protein (for example, one or more types selected from enzyme activities such as Rhodane activity and Tiocarboxylation activity) Activity) and a mutant protein consisting of an amino acid sequence in which deletion, substitution, insertion and / or addition of one to a plurality of amino acid residues has occurred with respect to the amino acid sequence of this protein.
  The mutation site and number of amino acids in the mutant protein are not particularly limited as long as the mutant protein retains substantially the same quality of activity as the original protein, but the number of mutations is, for example, 1 to 50, 1 -40, 1-30, 1-25, 1-20, 1-15, 1-10, 1-9, 1-8, 1-7, 1-6 (1 To several), 1 to 5, 1 to 4, 1 to 3, 1 to 2, and 1. In general, the smaller the number of mutations, the better. Further, such a mutant protein has the amino acid sequence of SEQ ID NO: 2 and about 70% or more, 75% or more, 80% or more, 85% or more, 90% or more, 91% or more, 92% or more, 93% or more, Contains a protein having an amino acid sequence having 94% or more, 95% or more, 96% or more, 97% or more, 98% or more, 99% or more identity and substantially the same activity as the original protein . In general, the larger the homology value, the better.
  The MOCS3 protein includes a “partial peptide” of the MOCS3 protein. The partial peptide of the MOCS3 protein is a partial peptide consisting of a partial amino acid sequence of the amino acid sequence of the MOCS3 protein (SEQ ID NO: 2), and preferably has the same activity as that of the aforementioned MOCS3 protein Any one can be used. For example, in the amino acid sequence represented by SEQ ID NO: 2, an amino acid consisting of at least 20, preferably at least 50, more preferably at least 70, more preferably at least 100, and most preferably at least 200 amino acid residues Examples thereof include a polypeptide having a sequence. Preferably, these polypeptides contain an amino acid sequence corresponding to the portion involved in the activity of the MOCS3 protein. Moreover, the partial peptide used in the present invention is one or more of the above-described polypeptides in the amino acid sequence (for example, about 1 to 20, more preferably about 1 to 10, even more preferably 1). (About ˜5) amino acid residues may be changed by deletion, addition, substitution, or insertion.
  The MOCS3 protein used in the present invention can be prepared from cells or tissues expressing the protein. In addition, these proteins can be synthesized by a known peptide synthesizer, or can be prepared by a recombinant method using an appropriate host cell selected from prokaryotes or eukaryotes. The MOCS3 protein used in the present invention may be derived from any species, but is preferably derived from a human.
  “Substantially the same activity” indicates that these activities are qualitatively equivalent. Therefore, the enzyme activity (Rhodanese activity, Tiocarbylation activity, etc.) is equivalent (for example, about 0.01 to 100 times, preferably about 0.5 to 20 times, more preferably about 0.5 to 2 times). Preferably, quantitative factors such as the degree of activity and the molecular weight of the protein may be different. The measurement of enzyme activity is described in Matties, A. et al. et al. Although it can carry out according to the well-known method as described in literatures, such as (2004) PNAS 101 (16), 5946-5951, it can measure according to the screening method described later, for example.
  The identity of the amino acid sequence and base sequence is determined by the algorithm BLAST (proc. Natl. Acad. Sci. USA 872264-2268, 1990; proc. Natl. Acad. Sci USA 90: 5873, 1993) by Carlin and Arthur. Can be determined. Programs called BLASTN and BLASTX based on the BLAST algorithm have been developed (Altschul SF, et al: J Mol Biol 215: 403, 1990). When analyzing a base sequence using BLASTN, parameters are set to, for example, score = 100 and wordlength = 12. When analyzing an amino acid sequence using BLASTX, parameters are set to score = 50 and wordlength = 3, for example. When using BLAST and Gapped BLAST programs, the default parameters of each program are used.
  In this specification, the term “cancer therapeutic agent” includes anticancer agents, cancer metastasis inhibitors, cancer cell apoptosis inducers, cancer cell proliferation inhibitors, cancer cell infiltration inhibitors, cancer preventive agents, and the like. Used in meaning. In the present specification, the terms “cancer (or cancer)” and “tumor” are used as terms having the same meaning.
1.1 Cancer therapeutic agent containing a MOCS3 gene expression inhibitor
  In one embodiment, the present invention provides a cancer therapeutic agent containing a MOCS3 gene expression inhibitor as an active ingredient.
  In the present specification, the “MOCS3 gene expression inhibitor” is not limited as long as it inhibits the expression of MOCS3 gene. For example, (i) a substance that inhibits transcription from MOCS3 gene to MOCS3 mRNA; And (ii) a substance that inhibits translation of MOCS3 mRNA into MOCS3 protein.
  Examples of substances that inhibit transcription from the MOCS3 gene to MOCS3 mRNA include:
(A) an antisense nucleic acid against the MOCS3 gene or a part thereof,
(B) a decoy nucleic acid for the MOCS3 gene or a part thereof,
(C) a MOCS3 gene variant that acts dominantly on the MOCS3 gene or a part thereof, or
(D) Other transcription inhibitor compounds
Etc. are included.
  Examples of substances that inhibit translation from MOCS3 mRNA to MOCS3 protein include:
(E) a polynucleotide having an RNAi action on MOCS3 mRNA or a part thereof (eg, siRNA),
(F) an antisense polynucleotide against MOCS3 mRNA or a part thereof;
(G) a polynucleotide having ribozyme activity against MOCD3 mRNA or a part thereof, or
(H) Other translation inhibitory compounds
Etc. are included.
  In the present specification, “nucleic acid” means RNA or DNA. The “nucleic acid” herein may contain not only purine and pyrimidine bases but also those having other modified heterocyclic bases. Such modifications may include methylated purines and pyrimidines, acylated purines and pyrimidines, acylated purines and pyrimidines, or other heterocycles. Modified nucleosides and modified nucleotides may also be modified at the sugar moiety, eg, one or more hydroxyl groups are replaced by halogens, aliphatic groups, etc., or functional groups such as ethers, amines, etc. It may be converted to.
  In the cancer therapeutic agent of the present invention, a nucleic acid having an action of inhibiting the expression of MOCS3 gene by the RNAi effect can be used as an active ingredient. RNAi refers to a phenomenon in which, when a double-stranded RNA having the same or similar sequence as a target gene sequence is introduced into a cell, expression of the introduced foreign gene and target endogenous gene are both inhibited. Examples of RNA used herein include double-stranded RNA that causes RNA interference of 19 to 30 bases in length, such as dsRNA (double strand RNA), siRNA (small interfering RNA), or shRNA (short hairpin RNA). . Such RNA can be locally delivered to a desired site by a delivery system such as a liposome, and can be locally expressed using a vector capable of generating the double-stranded RNA. Methods for preparing and using such double-stranded RNA (dsRNA, siRNA or shRNA) are known from many literatures (Japanese Patent Publication No. 2002-516062; US Publication No. 2002 / 086356A; Nature Genetics, 24 (2), Feb., 180-183; Genesis, 26 (4), April, 240-244; Nature, Spe. 21, 407: 6802, 319-20; Genes & Dev., Vol. ), Apr. 16, 948-958; Proc. Natl. Acad. Sci. USA., 99 (8), 16 Apr., 5515-5520; Science, 296 (5567), 19 Apr., 550-553; Natl.Acad.Sci.USA, Apr. 0, 99: 9, 6047-6052; Nature Biotechnology, Vol. 20 (5), May, 497-500; Nature Biotechnology, Vol. 20 (5), May, 500-508; Nucleic Acids Res., May 15 and the like. ).
  The length of the double-stranded RNA exhibiting the RNAi effect used in the present invention is usually 19 to 30 bases, preferably 20 to 27 bases, more preferably 21 to 25 bases, and most preferably 21 to 23 bases. In the present invention, specifically, the following siRNA (used in Example 3) can be used.

  In this specification, “antisense nucleic acid” or “antisense polynucleotide” has a polynucleotide complementary to at least a part of a DNA region of interest, and the polynucleotide is at least one of the region. It means a nucleic acid capable of hybridizing with a part. The antisense nucleic acid of the present invention is RNA, DNA, or a modified nucleic acid (RNA, DNA). The antisense nucleic acid of the present invention is RNA, DNA, or a modified nucleic acid (RNA, DNA). They may be double stranded DNA, single stranded DNA, double stranded RNA, single stranded RNA, or even a DNA: RNA hybrid. Specific examples of modified nucleic acids include, but are not limited to, nucleic acid sulfur derivatives and thiophosphate derivatives, and those that are resistant to degradation of polynucleotide amides and oligonucleotide amides. .
  The antisense nucleic acid used is linked downstream of a suitable promoter, and preferably a sequence containing a transcription termination signal is linked on the 3 'side. The nucleic acid thus prepared can be transformed into a desired animal by using a known method. The sequence of the antisense nucleic acid is preferably a sequence complementary to the endogenous gene or a part thereof possessed by the animal to be transformed, but it is not completely complementary as long as the gene expression can be effectively suppressed. May be.
  For example, designing an antisense sequence complementary to the untranslated region near the 5 'end of the mRNA of the MOCS3 gene is effective for inhibiting translation of the gene. A sequence complementary to the coding region or 3'-untranslated region can also be used. Antisense nucleic acid effective for inhibiting gene translation is about 70% or more, preferably about 80% or more, more preferably about 90% or more, most preferably about 95% or more complement to the target gene transcript. Have sex.
  In order to effectively suppress the expression of a target gene using an antisense nucleic acid, the length of the antisense nucleic acid is at least about 10 bases (for example, about 10 to 40 bases), preferably about 15 bases or more, More preferably, it is about 100 bases or more, More preferably, it is about 500 bases or more. Antisense nucleic acids can be designed with reference to known literature (for example, Hirashima and Inoue, Shinsei Kagaku Kogaku Lecture 2, Replication and Expression of Nucleic Acid IV Gene, edited by the Japanese Biochemical Society, Tokyo Chemical Dojin, 1993, p. 319). -347), J. et al. Kawakami et al. Pharm Tech Japan. Vol. 8, p. 247, 1992; Vol. 8, p. 395, 1992; T.A. Crooke et al. , Ed. , Antisense Research and Applications, CRC Press, 1993, etc.).
  In the cancer therapeutic agent of the present invention, a nucleic acid having a ribozyme activity that specifically cleaves a transcription product of the MOCS3 gene can be used as an active ingredient. As used herein, “ribozyme activity” refers to a nucleic acid that specifically cleaves mRNA, which is a transcription product of a target gene. Some ribozymes have a size of 400 nucleotides or more, such as group I intron type or M1 RNA contained in RNaseP, but some have an active domain of about 40 nucleotides called hammerhead type or hairpin type ( Protein Nucleic Acid Enzyme, 1990, 35, p. 2191). For the hammerhead ribozyme, see, for example, FEBS Lett, 1988, 228, p. 228; FEBS Lett, 1988, 239, p. 285; protein nucleic acid enzyme, 1990, 35, p. 2191; Nucl Acids Res, 1989, 17, p. 7059 and the like can be referred to. For hairpin ribozymes, see, for example, Nature, 1986, 323, p. 349; Nucl Acids Res, 1991, 19, p. 6751; Hiroshi Kikuchi, Chemistry and Biology, 1992, 30, p. 112 and the like can be referred to. By specifically cleaving the transcript of the MOCS3 gene in the present invention using such a ribozyme, the expression of the gene can be inhibited.
  Furthermore, the present invention can use compounds other than nucleic acids that inhibit the transcriptional activity of the MOCS3 gene as active ingredients. Such a compound is, for example, a compound that binds to a factor involved in the expression / transcription of the MOCS3 gene. Such a compound may be a natural product or a synthetic compound. Such a compound can be obtained by a screening method described later.
1.2 Cancer therapeutic agent containing an inhibitor of MOCS3 protein activity
  In another embodiment, the present invention also provides a cancer therapeutic agent containing a MOCS3 protein activity inhibitor.
  In the present specification, the “MOCS3 protein activity inhibitor” includes, for example,
  (A) an antibody that binds to the MOCS3 protein,
  (B) a MOCS3 protein variant having a dominant negative property with respect to the MOCS3 protein, or
  (C) Compound that binds to MOCS3 protein (excluding the above antibody and mutant)
Etc. are included.
  As used herein, “antibody” means an antibody that reacts with the full length or fragment of a protein. The form of the antibody of the present invention is not particularly limited, so long as it binds to the MOCS3 protein of the present invention, in addition to the above polyclonal antibody and monoclonal antibody, human antibodies, humanized antibodies by genetic recombination, antibody fragments thereof, Antibody modifications are also included. Antibodies that bind to MOCS3 protein (anti-MOCS3 antibodies) can be prepared by methods known to those skilled in the art. Details of the anti-MOCS3 antibody will be described later.
  As used herein, “MOCS3 protein mutant having a dominant negative property with respect to the MOCS3 protein” means a function of eliminating or reducing the activity of an endogenous wild-type MOCS3 protein by expressing a gene encoding the same. (Refer to Kunihiro Tsuchida, Gene Activity Inhibition Experiment, edited by Yoshikazu Tahira, Yodosha (2001) 26-32, etc.).
  Furthermore, in the present invention, as a substance capable of inhibiting the activity of the MOCS3 protein, a compound other than the above antibody or mutant that binds to the MOCS3 protein can be used as an active ingredient. Such compounds are, for example, compounds that bind to MOCS3 protein and inhibit its activity. Such a compound may be a natural product or a synthetic compound. Such a compound can be obtained by a screening method described later.
  The substance capable of inhibiting the activity of the above-described MOCS3 protein of the present invention can be used as a cancer therapeutic agent.
2. Method for screening a substance that inhibits the activity or expression of MOCS3 protein
  The present invention also provides a method for screening a candidate compound having a cancer suppressing action.
  One preferred embodiment is a method using as an index the binding between the MOCS3 protein and the test compound. Usually, a compound that binds to the MOCS3 protein is expected to have an effect of inhibiting the activity of the MOCS3 protein. Here, the compound preferably binds to the active site of the MOCS3 protein. In this method, first, the MOCS3 protein is contacted with a test compound. The MOCS3 protein may be, for example, a purified form of the MOCS3 protein, a form expressed intracellularly or extracellularly, or a form bound to an affinity column, depending on the indicator for detecting binding to the test compound. . The test compound used in this method can be appropriately labeled as necessary. Examples of the label include a radiolabel and a fluorescent label.
  Next, in this method, the binding between the MOCS3 protein and the test compound is detected.
  There is no restriction | limiting in particular as a test compound used for this method. For example, natural compounds, organic compounds, inorganic compounds, proteins, peptides and other single compounds, as well as compound libraries, gene library expression products, cell extracts, cell culture supernatants, fermented microorganism products, marine organism extracts Products, plant extracts and the like, but are not limited thereto.
  The binding between the MOCS3 protein and the test compound can be detected by, for example, a label attached to the test compound bound to the MOCS3 protein. In addition, a change in the activity of the MOCS3 protein caused by the binding of the test compound to the MOCS3 protein expressed inside or outside the cell can also be detected as an index. The binding activity between the protein and the test compound can be measured by a known method (for example, measurement of nitrate reductase activity or sulfurtransferase activity (Matties, A. et al. (2004) PNAS 101 (16), 5946-). 5951)).
  In this method, a test compound that binds to MOCS3 protein and inhibits its activity is then selected.
  The compound isolated by this method is expected to have a cancer suppressing action and is useful as a cancer therapeutic agent.
  Another embodiment of the screening method of the present invention is a method using the expression of the MOCS3 gene as an index.
  In this method, first, a test compound is brought into contact with a cell expressing the MOCS3 gene. Examples of the origin of the “cell” used include, but are not limited to, cells derived from humans, mice, cats, dogs, cows, sheep, birds, pets, livestock, and the like. As the “cell expressing the MOCS3 gene”, a cell expressing an endogenous MOCS3 gene or a cell into which an exogenous MOCS3 gene has been introduced and expressing the gene can be used. A cell in which an exogenous MOCS3 gene is expressed can be usually prepared by introducing an expression vector into which the MOCS3 gene is inserted into a host cell. The expression vector can be prepared by general genetic engineering techniques.
  The test compound used in this method is not particularly limited. For example, a natural compound, an organic compound, an inorganic compound, a protein, a single compound such as a peptide, a compound library, an expression product of a gene library, a cell Extracts, cell culture supernatants, fermented microorganism products, marine organism extracts, plant extracts and the like are used.
  The “contact” of the test compound to the cell expressing the MOCS3 gene is usually performed by adding the test compound to the culture medium of the cell expressing the MOCS3 gene, but is not limited to this method. When the test compound is a protein or the like, “contact” can be performed by introducing a DNA vector expressing the protein into the cell.
  In this method, the expression level of the MOCS3 gene is then measured. Here, “gene expression” includes both transcription and translation. The gene expression level can be measured by methods known to those skilled in the art. For example, mRNA can be extracted from cells expressing the MOCS3 gene according to a conventional method, and the transcription level of the gene can be measured by performing Northern hybridization or RT-PCR using this mRNA as a template. Alternatively, the promoter region of the MOCS3 gene is isolated according to a conventional method, and a downstream of the marker gene (for example, a gene that can be detected using luminescence, fluorescence, color development, etc. of luciferase, GFP, galactosidase, etc. as an index, but is not limited thereto. The transcription level of the gene can also be measured by observing the activity of the marker gene. Moreover, the translation level of a gene can also be measured by recovering a protein fraction from cells expressing the MOCS3 gene and detecting the expression of the MOCS3 protein by electrophoresis such as SDS-PAGE. Furthermore, it is also possible to measure the translation level of a gene by detecting the expression of the protein by performing Western blotting using an antibody against the MOCS3 protein. The antibody used for detecting the MOCS3 protein is not particularly limited as long as it is a detectable antibody. For example, both a monoclonal antibody and a polyclonal antibody can be used.
  In this method, a compound that decreases the expression level is then selected as compared to the case where the test compound is not contacted (control). The compound thus selected becomes a candidate compound for a cancer therapeutic agent.
3. Anti-MOCS3 antibody and therapeutic agent, complex and composition containing this antibody
  The present invention also provides an anti-MOCS3 antibody, a cancer therapeutic agent containing the antibody, and the like. In one preferred embodiment of the invention, the cancer therapeutic agent is used for cancer targeted therapy or targeted drug delivery.
  3.1 Anti-MOCS3 antibody
  In the present specification, “anti-MOCS3 antibody” includes an antibody that specifically binds to MOCS3 protein (including fragments (partial peptides) or salts thereof). The anti-MOCS3 antibody used in the present invention may be a polyclonal antibody or a monoclonal antibody. The class of the antibody is not particularly limited, and includes antibodies having any isotype such as IgG, IgM, IgA, IgD, or IgE. IgG or IgM is preferable, and IgG is more preferable in consideration of ease of purification. Further, the term “antibody” as used herein is used to mean any antibody fragment or derivative, for example, Fab, Fab ′₂, CDR, humanized antibody, multifunctional antibody, single chain antibody (ScFv) and the like. The antibody of the present invention can be produced by a known method. Methods for producing such antibodies are well known in the art (see, for example, Harlow E. & Lane D., Antibody, Cold Spring Harbor Laboratory Press (1988)).
(1) Preparation of antigen
  In the present invention, the protein used as the sensitizing antigen is usually the MOCS3 protein or a salt thereof. The MOCS3 protein also includes a partial peptide thereof, which is not limited to, for example, a fragment of the amino acid sequence of SEQ ID NO: 2, for example, 20 or more, 40 or more, 60 It is a partial peptide having at least 80, at least 100, and at least 100 consecutive amino acid sequence portions. As these fragments, for example, amino (N) terminal fragments and carboxy (C) terminal fragments are used. In the partial peptide used in the present invention, one or more (preferably about 1 to 10, more preferably several (1 to 6)) amino acid residues in the amino acid sequence are deleted or substituted. , Inserted and / or added. As the salt of the MOCS3 protein or its partial peptide used here, for example, a salt with an inorganic acid (for example, hydrochloric acid, sulfuric acid) or a salt with an organic acid (for example, acetic acid, formic acid, propionic acid) is used. . The MOCS3 protein of the present invention used as a sensitizing antigen for obtaining an antibody is not limited to the animal species from which it is derived, but is preferably a protein derived from a mammal such as a mouse or a human, and particularly preferably a protein derived from a human.
(2) Preparation of monoclonal antibody against MOCS3 protein
(I) Collection of antibody-producing cells
  The above-described MOCS3 protein, partial peptide thereof or salt thereof (in the present specification, these are collectively referred to as “MOCS3 protein”) as an antigen, and mammals such as rats, mice, rabbits, etc. To be administered. The dose of the antigen per animal is 0.1 to 100 mg when no adjuvant is used, and 1 to 100 μg when an adjuvant is used. Examples of adjuvants include Freund's complete adjuvant (FCA), Freund's incomplete adjuvant (FIA), and aluminum hydroxide adjuvant. Immunization is performed mainly by injecting intravenously, subcutaneously or intraperitoneally. The immunization interval is not particularly limited, and immunization is performed 1 to 10 times, preferably 2 to 5 times at intervals of several days to several weeks, preferably 2 to 5 weeks. Then, antibody-producing cells are collected 1 to 60 days, preferably 1 to 14 days after the final immunization day. Examples of antibody-producing cells include spleen cells, lymph node cells, peripheral blood cells, etc., but spleen cells or local lymph node cells are preferred.
(Ii) Cell fusion
  In order to obtain a hybridoma, cell fusion between antibody-producing cells and myeloma cells is performed. As myeloma cells to be fused with antibody-producing cells, generally available cell lines of animals such as mice can be used. The cell line used has drug selectivity and cannot survive in a HAT selection medium (including hypoxanthine, aminopterin, and thymidine) in an unfused state, but can survive only in a state fused with antibody-producing cells. Those having the following are preferred. Examples of myeloma cells include X63Ag. Examples include mouse myeloma cell lines such as 8.653, NSI / 1-Ag4-1, NS0 / 1, and rat myeloma cell lines such as YB 2/0.
  Next, the myeloma cell and the antibody-producing cell are fused. Cell fusion is performed in animal cell culture media such as serum-free DMEM, RPMI-1640 medium, 1 × 10⁶~ 1x10⁷Cells / ml of antibody-producing cells and 2 × 10⁵~ 2x10⁶Cells / ml myeloma cells are mixed (cell ratio of antibody-producing cells to myeloma cells is preferably 2: 1 to 3: 1), and a fusion reaction is performed in the presence of a cell fusion promoter. As the cell fusion promoter, polyethylene glycol having an average molecular weight of 1000 to 6000 daltons can be used. Alternatively, antibody-producing cells and myeloma cells can be fused using a commercially available cell fusion device utilizing electrical stimulation (for example, electroporation).
(Iii) Selection and cloning of hybridomas
  The target hybridoma is selected from the cells after cell fusion treatment. As the method, the cell suspension is appropriately diluted with, for example, a fetal bovine serum-containing RPMI-1640 medium, and then 3 × 10 3 on a microtiter plate.⁵Seed per well / well, add selective medium to each well, and then replace the selective medium appropriately and culture. As a result, cells that grow from about 14 days after the start of culture in the selective medium can be obtained as hybridomas.
  Next, it is screened whether the antibody which reacts with MOCS protein exists in the culture supernatant of the hybridoma which has propagated. Hybridoma screening is not particularly limited, and may be performed according to ordinary methods. For example, a part of the culture supernatant contained in a well grown as a hybridoma can be collected and screened by enzyme immunoassay, radioimmunoassay, or the like. Cloning of fused cells is performed by the limiting dilution method or the like. Finally, a hybridoma that is a cell producing a monoclonal antibody that reacts with the MOCS protein is established.
  (Iv) Collection of monoclonal antibody
  As a method for collecting a monoclonal antibody from the hybridoma obtained as described above, a normal cell culture method or ascites formation method can be employed. In the cell culture method, the hybridoma is cultured in an animal cell culture medium such as RPMI-1640 medium containing 10% fetal bovine serum, MEM medium, or serum-free medium (eg, 37 ° C., 5% CO 2).₂(Concentration) for 7 to 14 days, and antibodies are obtained from the culture supernatant. In the case of the ascites formation method, the hybridoma is about 1 × 10 6 in the abdominal cavity of a mammal derived from a myeloma cell.⁷Individually administered, the hybridoma is proliferated in large quantities. And ascites is collected after 1-2 weeks. When antibody purification is required in the antibody collection method, known methods such as ammonium sulfate salting-out method, ion exchange chromatography, gel filtration, affinity chromatography are appropriately selected, or a combination thereof is used. Can be purified.
(3) Preparation of polyclonal antibody against MOCS3 protein
  First, the antigen described above is administered to mammals such as rats, mice, rabbits and the like. The dose of the antigen per animal is 0.1 to 100 mg when no adjuvant is used, and 10 to 1000 μg when an adjuvant is used. Examples of adjuvants include Freund's complete adjuvant (FCA), Freund's incomplete adjuvant (FIA), and aluminum hydroxide adjuvant. Immunization is performed mainly by injecting intravenously, subcutaneously or intraperitoneally. The immunization interval is not particularly limited, and immunization is performed 1 to 10 times, preferably 2 to 5 times at intervals of several days to several weeks, preferably 2 to 5 weeks. And 6 to 60 days after the final immunization, the antibody titer is measured by enzyme immunoassay (ELISA (enzyme-linked immunosorbent assay) or EIA (enzyme immunoassay)), radioimmunoassay (RIA; radioimmunoassay), etc. On the day when the maximum antibody titer is shown, blood is collected to obtain antiserum.
  Next, for example, an antibody (column adsorption fraction) that reacts with the MOCS3 protein is collected by applying a polyclonal antibody in the antiserum to an affinity column fixed with the MOCS3 protein. The reactivity of the polyclonal antibody in the antiserum against the MOCS3 protein can be measured by an ELISA method or the like.
(4) Antibody fragments, etc.
  Fab or Fab '₂Fragments can be generated by digestion with proteases (eg, pepsin or papain) by conventional methods. Humanized antibodies can be obtained by methods such as those described in Riechmann et al. (Riechmann J Mol Biol. Oct 5; 203 (3): 825-8, 1988), and Jones et al. (Jones et al. Nature 321: 522-525, 1986). Can be prepared by one of the following:
  The chimeric antibody is exemplified by “Experimental Medicine (Special Issue), Vol. 1.6, No. 10, 1988”, Japanese Patent Publication No. 3-73280, and the like, and the humanized antibody is exemplified by “Nature Genetics”. , Vol.15, p.146-156, 1997 "," Nature Genetics, Vol.7, p.13-21, 1994 ", Japanese translation of PCT publication No. 4-504365, International application publication WO94 / 25585, etc. "Nikkei Science, June issue, pages 40 to 50, 1995", "Nature, Vol. 368, p. 856-859, 1994", JP-T 6-500263, etc. be able to. The antibody that binds to the MOCS3 protein of the present invention may be used for the purpose of, for example, suppressing cancer cell growth or metastasis. When the obtained antibody is used for the purpose of administering it to the human body (antibody treatment), a human antibody or a human-type antibody is preferable in order to reduce immunogenicity.
  When used as a diagnostic agent, the antibody may be labeled with a labeling substance (for example, a radioisotope, a fluorescent substance, etc.) for monitoring or the like. If necessary, it can be labeled with a radioactive substance, a fluorescent compound, or the like. Among the most common fluorescent labeling compounds are fluorescein isothiocyanate, rhodamine, phycoerythrin and fluorescamine. Similarly, the antibody MOCS3 antibody can be labeled with a bioluminescent compound. The presence of the bioluminescent protein is measured by detecting the presence of fluorescence. Important bioluminescent compounds for this labeling purpose are luciferin, luciferase and aequorin.
  The antibody of the present invention can be used to specifically detect MOCS3 protein or the like present in a subject such as a body fluid or tissue. It can also be used for production of antibody columns used to purify MOCS3 protein, etc., detection of MOCS3 protein, etc. in each fraction during purification, analysis of the behavior of MOCS3 protein in test cells, etc. it can,
  3.2 Complex containing anti-MOCS3 antibody, etc.
  In addition, the anti-MOCS3 antibody used in the present invention can be an agent having a neutralizing activity that attenuates the activity of the antigen in the therapeutic agent or diagnostic agent of the present invention. Accordingly, it can be used in combination with other drugs for producing a therapeutic effect. Accordingly, the present invention, in another aspect, provides a complex of an anti-MOCS3 antibody and another agent for use in targeted therapy or targeted imaging of cancer (eg, colon cancer), such as Also provided are compositions containing such composites. According to such an aspect, the anti-MOCS3 antibody used in the present invention can be used to deliver another drug having a therapeutic effect or a labeling agent for diagnosis to a target site that highly expresses the MOCS3 protein. it can.
  Examples of the “other drug” used in the present invention include a viral vector or a non-viral vector for gene transfer to a target, such as a radioisotope, a therapeutic protein, or a small molecule drug.
  In the present invention, examples of the “radioisotope” include fluorine-18, iodine-125 (¹²⁵I) and radioactive halogen elements such as iodine-131. These radioactive halogen elements can be widely used as radiotherapeutic agents or radiodiagnostic agents by labeling antibodies and peptides in the same manner as the above-mentioned radioactive metal elements. For example,¹²⁵I or¹³¹Iodination with I can be bound to an antibody or antibody fragment by a known method such as the chloramine T method. For diagnostic purposes, technetium-99m, indium-111 and gallium-67 (⁶⁷Ga), etc., and for treatment, yttrium-90 (⁹⁰Y), rhenium-186 (¹⁸⁶Re) or rhenium-188 (¹⁸⁸Re) etc. can be used. When the antibody is labeled with a radioisotope, a metal chelating agent is usually used. Known metal chelating agents include EDTA, DTPA, diaminodithio compounds, cyclam, and DOTA. These chelating agents may be preliminarily bound to the antibody and then labeled with a radioactive metal, or there may be a method in which a radiometal chelate is formed and then bound to the antibody and labeled.
  In the present invention, as examples of “therapeutic proteins”, cytokines that activate cells responsible for immunity are suitable. For example, human interleukin 2, human granulocyte-macrophage-colony stimulating factor, human macrophage colony stimulating factor, Human interleukin 12 etc. are mentioned. Moreover, in order to directly kill colon cancer cells, toxins such as ricin and diphtheria toxin can be used. For example, for a fusion antibody with a therapeutic protein, a cDNA encoding the fusion protein is constructed by linking the cDNA encoding the therapeutic protein to a cDNA encoding the antibody or antibody fragment, and this DNA is used for prokaryotic or eukaryotic organisms. The fusion antibody can be produced by inserting the expression vector into a prokaryotic organism or a eukaryotic organism and expressing the expression vector.
  “Small molecule drug” is used herein to mean a diagnostic or therapeutic compound other than “radioisotope”, “therapeutic protein” and the like. Examples of the “small molecule drug” include alkylating agents such as nitrogen mustard and cyclofasfamide, antimetabolites such as 5-fluorouracil and methotrexate, and antibiotics such as daunomycin, bleomycin, mitomycin C, daunorubicin and doxorubicin. Substances, plant alkaloids such as vincristine, vinblastine, vindesine, anticancer agents such as hormonal agents such as tamoxifen, dexamethasone (Clinical Oncology (1996 Clinical Oncology Society, Cancer and Chemotherapy)), or hydrocortisone, prednisone, etc. Steroids, non-steroids such as aspirin and indomethacin, immunomodulators such as gold thiomalate and penicillamine, immunosuppressants such as cyclophosphamide and azathioprine, chlor maleate And anti-inflammatory agents such as phenylamine and clemacytin (inflammation and anti-inflammatory therapy 1982, Yakuhin Shuppan Co., Ltd.). For example, as a method of binding daunomycin and antibody, a method of binding between daunomycin and the amino group of the antibody via glutaraldehyde, a method of binding the amino group of daunomycin and the carboxyl group of the antibody via water-soluble carbodiimide, etc. Can be given.
  As an example of a “viral vector”, a viral vector modified so as to be able to bind to the anti-MOCS3 antibody of the present invention can be used (for example, adenoviral vector (Wang, P., et al. (1995) Somatic Cell). and Molec. Genet. 21, 429-441), retroviral vectors (Naviaux RK, et al. (1996) J. Virol 70, 5701-5705), lentiviral vectors (Naldini, L. (1998) Curr. Opin.Biotechnol.9,457-463)). Such viral vectors include genes that exert therapeutic effects such as inducing apoptosis of cancer cells at a target site (eg, colon cancer), such as cell proliferation-related genes, apoptosis-related genes, and immunoregulatory genes. (Therapeutic gene) is incorporated. Viral vectors that bind to anti-MOCS3 antibodies can be targeted to sites where antigens recognized by anti-MOCS3 antibodies (ie, MOCS3) when administered to patients in need of gene therapy with anti-MOCS3 antibodies. .
  The anti-MOCS3 antibody and the other agent can be combined chemically or genetically. Here, “chemical bond” includes ionic bond, hydrogen bond, covalent bond, bond by intermolecular force, bond by hydrophobic interaction, etc., and “genetic bond” For example, a binding mode between an antibody and a therapeutic protein when a fusion protein composed of an antibody and a therapeutic protein is produced using a technique such as gene recombination is included.
4). Formulation and formulation administration method
  A cancer therapeutic agent containing the MOCS3 gene expression inhibitor of the present invention, a cancer therapeutic agent containing a MOCS3 protein activity inhibitor, a therapeutic agent containing the anti-MOCS3 antibody of the present invention, or an anti-agent used in the present invention The MOCS3 antibody is chemically or genetically conjugated to a radioisotope, therapeutic protein, small molecule drug, and any viral or non-viral vector carrying a therapeutic gene, or any combination thereof. The therapeutic agent can be formulated based on a known technique.
  In formulating the therapeutic agent of the present invention, a pharmaceutically acceptable carrier can be added as necessary according to a conventional method. For example, surfactants, excipients, coloring agents, flavoring agents, preservatives, stabilizers, buffering agents, suspending agents, tonicity agents, binders, disintegrating agents, lubricants, fluidity promoters, taste masking However, the present invention is not limited thereto, and other commonly used carriers can be appropriately used. Specifically, light anhydrous silicic acid, lactose, crystalline cellulose, mannitol, starch, carmellose calcium, carmellose sodium, hydroxypropylcellulose, hydroxypropylmethylcellulose, polyvinylacetal diethylaminoacetate, polyvinylpyrrolidone, gelatin, medium chain fatty acid triglyceride, Examples thereof include polyoxyethylene hydrogenated castor oil 60, sucrose, carboxymethylcellulose, corn starch, and inorganic salts.
  Examples of the dosage form of the therapeutic agent of the present invention include tablets, powders, pills, powders, granules, fine granules, soft / hard capsules, film coating agents, pellets, and sublingual agents as oral preparations. And pastes such as injections, suppositories, transdermal agents, ointments, plasters, liquids for external use, etc. You can choose. The MOCS3 protein activity (or MOCS3 gene expression) inhibitor as an active ingredient may be contained in an amount of 0.1 to 99.9% by weight.
  The dose of the active ingredient of the drug of the present invention varies depending on the administration subject, target organ, symptom, administration method and the like, but in the case of oral administration, for example, generally for a patient (as 60 kg) per day About 0.1 mg to 1,000 mg, preferably about 1.0 to 100 mg, more preferably about 1.0 to 50 mg. When administered parenterally, the single dose varies depending on the administration subject, target organ, symptom, administration method, etc. For example, in the form of an injection, for example, a patient (for 60 kg), It is convenient to administer about 0.01 to 30 mg per day, preferably about 0.1 to 20 mg, more preferably about 0.1 to 10 mg by intravenous injection. However, the final decision can be made as appropriate based on the judgment of a doctor or veterinarian in consideration of the type of dosage form, administration method, patient age and weight, patient symptoms, and the like.
  The preparation thus obtained can be administered to, for example, humans and other mammals (eg, rats, rabbits, sheep, pigs, cows, cats, dogs, monkeys, etc.). Also in the case of animals other than humans, the amount converted per 60 kg can be administered.
  The therapeutic agent of the present invention is cancer (for example, colorectal cancer, stomach cancer, lung cancer, breast cancer, prostate cancer, esophageal cancer, liver cancer, biliary tract cancer, spleen cancer, kidney cancer, bladder cancer, Prevention / treatment of uterine cancer (eg cervical cancer, endometrial cancer), testicular cancer, thyroid cancer, pancreatic cancer, ovarian cancer, brain tumor, blood tumor, etc., preferably colon cancer Used for the prevention and treatment of
  Since the agent of the present invention contains a MOCS3 protein activity inhibitor or MOCS3 gene expression inhibitor as an active ingredient, it can be used as an anticancer agent, a cancer metastasis inhibitor, a cancer cell apoptosis inducer, and the like. The types of cells, tissues, organs, or cancers of interest are not limited to specific ones. In addition, the agent of the present invention may contain both a MOCS3 protein activity inhibitor and a MOCS3 gene expression inhibitor.
  When an antisense nucleic acid is used in the therapeutic agent of the present invention, the antisense nucleic acid is administered alone or after being inserted into an appropriate vector such as a retrovirus vector, adenovirus vector, adenovirus associated virus vector, etc., and then administered according to known means. can do. Antisense nucleic acids can be formulated alone or with a physiologically acceptable carrier and administered via a gene gun or a catheter such as a hydrogel catheter.
  In the present invention, when a combination of a virus vector such as a recombinant adenovirus particle and an anti-MOCS3 antibody is used for cancer treatment, these may be used alone, but are generally pharmaceutically acceptable. Used with a carrier. As such a carrier, a carrier as described above and an aqueous isotonic solution such as water, physiological saline, glucose, human albumin and the like are preferable. Furthermore, additives, preservatives, preservatives, balances and the like that are commonly used in pharmaceutics can also be added. The pharmaceutical composition thus prepared can be administered by an appropriate administration form and administration route depending on the disease to be treated. Examples of the dosage form include emulsions, syrups, capsules, tablets, granules, injections, ointments and the like. When the anti-MOCS3 antibody-viral vector particle of the present invention or a pharmaceutical composition comprising the same is administered for treatment, it is usually 10 per adult.³-10¹⁵It is preferable to administer individual virus particles, but it may vary depending on the disease state and the nature of the target cell / tissue. The administration frequency may be once to several times a day, the administration period may be from one day to several months or more, and one set may be one to several injections, and multiple sets may be administered intermittently over a long period of time. Good. Moreover, the viral vector particle or viral vector nucleic acid molecule used in the present invention can be used for detection of specific cells and / or tissues, or diagnosis of disease states. For example, viral vector particles obtained by incorporating a detectable marker gene into a nucleic acid molecule of a viral vector and transfecting it into an appropriate host cell can be used in combination with an anti-MOCS3 antibody to detect and diagnose tumor cells. can do. Alternatively, it can be used to detect and diagnose tumor cells by binding a detectable label to the anti-MOCS3 antibody.
5). Cancer diagnostic agent and diagnostic method
  The present invention also provides a diagnostic agent for cancer. In one preferred embodiment, the diagnostic agent for cancer of the present invention is capable of hybridizing under stringent hybridization conditions to (a) an antibody against the MOCS3 protein, or (b) the MOCS3 gene or a partial nucleotide sequence thereof. A polynucleotide comprising a base sequence is contained.
  5.1 Diagnostic agent and diagnostic method using antibody MOCS3 antibody
  Since the antibody against the MOCS3 protein can specifically recognize the MOCS3 protein and the like, the MOCS3 protein in the test solution can be quantified. Specifically, the diagnostic method using the anti-MOCS3 antibody of the present invention includes, for example, (a) a step of bringing a subject-derived biological sample into contact with an antibody against MOCS3 protein, and (b) the antibody in the sample. And a step of detecting and / or quantifying the binding of the MOCS3 protein or a partial peptide thereof or a salt thereof. Preferably, in the step of detecting and / or quantifying, the labeled anti-MOCS3 antibody is used to detect and / or quantify the binding between the MOCS3 protein or a fragment thereof and the anti-MOCS3 antibody.
  In the present specification, “subject-derived biological sample” refers to a subject-derived tissue, cell, or body fluid (for example, blood (including whole blood, plasma, serum, etc.), urine, lymph, saliva, sweat, semen, etc.) including. In addition, “subject” is a human subject who usually receives or desires to undergo cancer screening, and includes a human subject suffering from or suspected of having cancer. . Examples of such cancers are colorectal cancer, stomach cancer, lung cancer, breast cancer, prostate cancer, esophageal cancer, liver cancer, biliary tract cancer, spleen cancer, kidney cancer, bladder cancer, uterus. Cancers (eg, cervical cancer, endometrial cancer), testicular cancer, thyroid cancer, pancreatic cancer, ovarian cancer, brain tumor, blood tumor, etc. are included, with colon cancer being particularly preferred.
  Immunoassays for detecting the expression of MOCS3 in a biological sample derived from a subject as described above were taken from a subject suspected of having cancer (eg, colon cancer) or at risk for cancer. It involves contacting the biological sample with an anti-MOCS3 antibody under conditions that produce specific antigen-antibody binding and then measuring the amount of immunospecific binding by the antibody. Such antibody binding is used to detect the presence and / or increased expression of the MOCS3 protein. In this case, detection of increased MOCS3 protein expression is an indicator of disease state. If necessary, the level of MOCS3 protein in the biological sample may be compared with the level of a healthy person who does not have cancer.
  In one embodiment of the immunoassay, for example, a biological sample such as a serum sample is brought into contact with a solid support or carrier such as nitrocellulose for the purpose of immobilizing all proteins present in the sample. The support is then washed with buffer and subsequently treated with detectably labeled anti-MOCS3 antibody. The solid support is then washed twice with buffer to remove unbound antibody. The amount of bound antibody on the solid support is measured according to well-known methods. The detection conditions suitable for each measurement can be appropriately determined by those skilled in the art using conventional test methods.
  In one method of detectably labeling an anti-MOCS3 antibody, the antibody is conjugated to an enzyme, such as that used in enzyme immunoassay (EIA) [Voiler, A. et al. “The Enzyme Linked Immunosorbent Assay” (ELISA), 1978, Diagnostic Horizons, 2: 1-7, Microbiological Associates Quarters, Microbiological Association. Pathol., 31: 507-520, 1978: Butier, JE, Meth. Enzymol., 73: 482-523, 1981] Fluorescence measurements by visible means, for example by spectrophotometric measurement of the enzyme bound to the antibody. Reaction with a suitable substrate, preferably a chromogenic substrate, in such a way that a chemical molecule is generated that can be detected by Enzymes that can be used to attach a detectable label to the antibody include, but are not limited to, peroxidase and alkaline phosphatase, which is also a colorimetric method using a chromogenic substrate for the enzyme. Can be achieved.
  Other methods that can be used in the present invention include radioimmunoassay (RIA), sandwich immunoassay, immunometric method, nephrometry, fluorescence immunoassay (FIA), time-resolved fluorescence immunoassay (TRFIA), enzyme immunization. Measurement method (EIA), Luminescence immunoassay (LIA), Electrochemiluminescence immunoassay (ECLIA), Latex agglutination method, Immunoprecipitation assay, Precipitation reaction method, Gel diffusion sedimentation reaction method, Immunodiffusion assay method, Aggregation Examples include an immunoassay selected from the group consisting of an elementary assay, a complement binding assay, an immunoradiometric assay, a fluorescence immunoassay, and a protein A immunoassay (WO 00/14227, page 39). Line 25 to page 42, line 8, EP1111047A2 paragraph [0115] page 19, line 35 to page 20, line 47 Reference).
  As described above, various diseases associated with MOCS3 protein dysfunction can be diagnosed by utilizing the in vivo MOCS3 protein quantification method using the antibody of the present invention. For example, when an increase in the concentration of MOCS3 protein is detected, for example, it is highly likely that the disease is caused by overexpression of MOCS3 protein (for example, cancer (eg, colon cancer)) or may be affected in the future. Can be diagnosed as high.
  The anti-MOCS3 antibody of the present invention can also be used for diagnosis in vivo. The preparation and use of antibody preparations that can be used herein are well known in the art. For example, for antibody-chelators, see Nucl. Med. Biol. 1990 17: 247-254. An antibody having a paramagnetic ion as a label used in magnetic resonance imaging is described in, for example, Magnetic Resonance in Medicine 1991 22: 339-342.
  5.2 Diagnostic agent and diagnostic method using polynucleotide (eg, DNA) probe
  In the diagnostic method of the present invention, a probe or primer designed based on the base sequence of the MOCS3 gene can be used. Specifically, such a diagnostic method includes, for example, (a) a biological sample derived from a subject and a polynucleotide comprising a base sequence capable of hybridizing under stringent hybridization conditions to the base sequence of the MOCS3 gene or a fragment thereof. Contacting with a nucleotide (probe), and (b) detecting and / or quantifying the hybridization between the polynucleotide in the sample and the MOCS3 gene or a fragment thereof.
  In the method of the present invention, the DNA of MOCS3 gene (or a gene fragment thereof) in a biological sample derived from a subject is detected and / or quantified using the probe. The length of the base sequence used as a probe is, for example, 12 or more bases, 15 or more bases, 18 or more bases, 21 or more bases, 24 or more bases, 27 or more bases, 30 or more bases, or a longer-length polynucleotide fragment. possible. For hybridization, the low, medium or high stringent conditions described above may be used. In the present specification, the “base sequence capable of hybridizing under stringent hybridization conditions to the base sequence of the MOCS3 gene or a fragment thereof” includes a base sequence complementary to the base sequence of the MOCS3 gene or a fragment thereof ( Antisense polynucleotide) is also included. Methods of probe and nucleic acid hybridization are known to those skilled in the art, for example, WO 89/06698, EP-A0200362, US Pat. No. 2,915,082, EP-A0063879, EP-A0173251, EP -A0128018.
  In the diagnostic method of the present invention, the target sequence can be detected or quantified using a known polynucleotide probe or primer for the MOCS3 gene using a known technique. Examples of such known techniques include Southern hybridization, Northern hybridization, RT-PCR method, PCR-SSCP method (Genomics, Vol. 5, pp. 874-879 (1989)), Proceedings of the National Academy of. Sciences of the United States of America, Vol. 86, 2766-2770 (1989)), FISH method, DNA chip or array CGH (Comparative Genomic Hybridization) method, and the like can be used. Quantitative detection can be performed by quantitative RT-PCR. The array CGH method is a method in which a chromosomal CGH method (Kallioniemi, A. et al. (1992) Science 258, 818-821) is applied, and genomic DNA fragments (BAC, PAC, YAC, etc.) covering a chromosomal region on a slide. ) And high-density spotted DNA chip, simultaneously hybridize cancer-derived DNA labeled with different dyes and normal DNA to genomic DNA fragments on the slide to detect their binding state. This is a method for detecting an abnormal DNA copy number in cancer with high resolution (Pinkel, D. et al. (1998) Nat. Genet. 20, 207-211).
  In the present invention, in order to detect whether or not the expression of MCOS3 gene is up-regulated, the mRNA level of MCOS3 in cells is determined based on a standard gene (housekeeping gene (for example, Shaper, N.L. Mammary Gland Biol. Neoplasmia 3 (1998) 315-324; Wu, Y. Y. and Rees, J. L., Acta Derm. Venereol. 80 (2000) 2-3) and preferably RT- It can also be compared by PCR.
  When the target sequence (DNA, mRNA, etc.) is detected and quantified by the method as described above and overexpression of the MOCS3 gene is confirmed, for example, a disease (for example, cancer (eg, cancer (eg: It can be diagnosed that there is a high possibility that it is colorectal cancer, cervical cancer)), or that it is highly likely to be affected in the future.
  5.3 Diagnostic kit
  The present invention also provides a kit for detecting and / or quantifying a MOCS3 protein or a fragment thereof in a body fluid sample of a subject containing an anti-MOCS3 antibody as a cancer marker. Furthermore, the MOCS3 gene or a fragment thereof in a biological sample derived from a subject, which contains a base sequence capable of hybridizing under stringent hybridization conditions to the MOCS3 gene or a part of the base sequence thereof, is detected and / or used as a cancer marker. Alternatively, a kit for quantification is also provided. These kits are used to detect cancer markers by the above-described immunological technique or hybridization method. Examples of such cancers include colon cancer, stomach cancer, lung cancer, breast cancer, prostate cancer, esophageal cancer, liver cancer, biliary tract cancer, spleen cancer, kidney cancer, bladder cancer, and uterus. Cancers (eg, cervical cancer, endometrial cancer), testicular cancer, thyroid cancer, pancreatic cancer, ovarian cancer, brain tumor, blood tumor, etc. are included, with colon cancer being particularly preferred.
  In the present specification, the term “cancer marker” refers to a subject's body fluid (eg, blood, urine, lymph, saliva, sweat, semen, etc.) or cells or tissues that are not derived from normal tissues, or It refers to a molecule that is selectively enhanced in cancer cells or tissues, and the presence of the molecule in the body fluid or cells or tissues of a subject indicates or indicates the presence of cancer.
  The kit of the first aspect contains a component for detecting and / or quantifying MOCS3 antigen (including MOCS3 protein and its partial peptide) in a body fluid sample from a subject. For example, if MOCS3 protein is detected and / or quantified by ELISA, such components may be used to detect and / or quantify the level of MOCS3 in, for example, tissue sections or body fluid samples such as blood and urine. Can be used. Such antibodies may be labeled with radioactivity, fluorescence, colorimetry, or enzyme label. The kit of the present invention may contain a labeled secondary antibody.
  The kit according to the second aspect includes a polynucleotide having a base sequence capable of hybridizing to the MOCS3 gene or a part of the base sequence under stringent hybridization conditions. For example, the kit of the present invention may contain the polynucleotide immobilized on a DNA chip.
  The kit of the present invention typically includes a container and a label in addition to a base sequence capable of hybridizing under stringent hybridization conditions to an anti-MOCS3 antibody, MOCS3 gene or a part of the base sequence. Yes. The label on or associated with the container may indicate that the drug is used to detect a colorectal cancer marker. In addition, other items such as instructions for use, labeled secondary antibodies, and the like may further be included.
  EXAMPLES Hereinafter, although this invention is demonstrated more concretely using an Example, the scope of the present invention is not limited by these Examples.

実施例２：大腸由来培養細胞株での遺伝子増幅度の検証
本実施例では、大腸がん患者において高頻度で高値な遺伝子領域について、大腸がん由来培養細胞株での増幅度を検証した。
＜サンプル調製＞
培養細胞株は、大腸がん由来の細胞株であるＲＫＯＥ６，Ｃａｃｏ２を使用した。培養細胞よりＢｌｏｏｄ ＆ Ｃｅｌｌ Ｃｕｌｔｕｒｅ ＤＮＡ Ｋｉｔ（ＱＩＡＧＥＮ）を使用して、キット添付のプロトコールに従い、ゲノムＤＮＡを抽出した。
＜アレイＣＧＨ＞
遺伝子領域の増幅を確認するために、アレイＣＧＨを実施した。方法の詳細は実施例１と同様に実施した。
結果
表３に、ＭＯＣＳ３遺伝子の大腸がん由来の細胞株での増幅度（Ｇ／Ｒ値）を示した。示されるように、大腸がん由来細胞株においても、ＢＡＣ Ｃｌｏｎｅ ＲＰ１１−３７９Ｄ４に位置している、ＭＯＣＳ３遺伝子で増幅が起きていることを見出した。

＜定量的ＰＣＲ＞
ＭＯＣＳ３遺伝子領域の増幅を確認するために、定量的ＰＣＲを実施した。定量的ＰＣＲは、ＳＹＢＲ Ｇｒｅｅｎ ＲＴ−ＰＣＲ Ｒｅａｇｅｎｔｓ（Ａｐｐｌｉｅｄ Ｂｉｏｓｙｓｔｅｍｓ）を使用して、添付のプロトコールに従い、７５００ Ｒｅａｌ−Ｔｉｍｅ ＰＣＲ Ｓｙｓｔｅｍ（Ａｐｐｌｉｅｄ Ｂｉｏｓｙｓｔｅｍｓ）を用いて実施した。プライマーは、以下の配列を合成し（ＯＰＥＲＯＮに合成委託）使用した。
プライマー配列：
５’−ＣＣＴＣＴＴＡＣＡＧＴＧＧＣＡＧＣＴＴＧＴＴＧ−３’（配列番号３）
５’−ＧＡＡＧＧＣＴＴＣＡＴＡＧＴＣＣＡＧＣＡＧＡＴＣ−３’（配列番号４）
結果
表４に、ＭＯＣＳ３遺伝子の大腸がん由来の細胞株での増幅度を示した。値は対照ＤＮＡ（正常）との相対値を示している。示されるように、大腸がん由来細胞株においても、ＭＯＣＳ３遺伝子領域に増幅が起きていることを見出した。

これらの結果により、大腸がん由来の細胞株（ＲＫＯＥ６，Ｃａｃｏ２）においても、ＭＯＣＳ３遺伝子が増幅していることが確認された。よって、がんにおけるＭＯＣＳ３遺伝子の機能解析に使用可能な培養細胞が選択された。
実施例３：大腸がん細胞株を用いたＲＮＡｉ解析による機能解析
本実施例では、大腸がん患者２００検体において高頻度に増幅が認められたＭＯＣＳ３遺伝子について、大腸がん由来の細胞株であり、且つ、ゲノムレベルで遺伝子の増幅が認められた細胞株（ＲＫＯＥ６）を用いて、ＲＮＡｉ解析を行い、その表現型を観察した。
＜ＲＮＡｉ解析＞
細胞株はＡＴＣＣより購入し、添付のプロトコールに従い培養を行った。ｓｉＲＮＡは遺伝子内の特異的な２１ｍｅｒを選択しその配列を標的とするｓｉＲＮＡを合成した（ＱＩＡＧＥＮに合成委託）。

ｓｉＲＮＡのＲＫＯＥ６細胞内への導入は、Ｏｌｉｇｏｆｅｃｔａｍｉｎｅ（Ｉｎｖｉｔｒｏｇｅｎ）を使用し、１００ｎＭのｓｉＲＮＡを添付のプロトコールに従い細胞に導入した。対照にはＮｅｇａｔｉｖｅ Ｃｏｎｔｒｏｌ ｓｉＲＮＡ（ＱＩＡＧＥＮ）を使用した。細胞に導入後４日間、倒立顕微鏡下で観察した。
＜定量的ＲＴ−ＰＣＲ解析＞
定量的ＲＴ−ＰＣＲ法を用いて、ｓｉＲＮＡの効果をｍＲＮＡレベルで検証した。ｓｉＲＮＡ導入後２４時間の細胞から、Ｍｉｃｒｏ−ｔｏ−Ｍｉｄｉ Ｔｏｔａｌ ＲＮＡ Ｐｕｒｉｆｉｃａｔｉｏｎ Ｓｙｓｔｅｍ（Ｉｎｖｉｔｒｏｇｅｎ）を使用して、添付のプロトコールに従い、全ＲＮＡを抽出した。その後、ＳｕｐｅｒＳｃｒｉｐｔ ＩＩＩ Ｆｉｒｓｔ−Ｓｔｒａｎｄ Ｓｙｎｔｈｅｓｉｓ Ｓｙｓｔｅｍ ｆｏｒ ＲＴ−ＰＣＲ（Ｉｎｖｉｔｒｏｇｅｎ）を使用して、添付のプロトコールに従い、ｃＤＮＡを合成した。
このｃＤＮＡを鋳型にして、定量的ＲＴ−ＰＣＲを実施した。定量的ＰＣＲは、ＳＹＢＲ Ｇｒｅｅｎ ＲＴ−ＰＣＲ Ｒｅａｇｅｎｔｓ（Ａｐｐｌｉｅｄ Ｂｉｏｓｙｓｔｅｍｓ）を使用して、添付のプロトコールに従い、７５００ Ｒｅａｌ−Ｔｉｍｅ ＰＣＲ Ｓｙｓｔｅｍ（Ａｐｐｌｉｅｄ Ｂｉｏｓｙｓｔｅｍｓ）を用いて実施した。プライマーは、以下の配列を合成し（ＯＰＥＲＯＮに合成委託）使用した。
プライマー配列：
５’−ＣＣＴＣＴＴＡＣＡＧＴＧＧＣＡＧＣＴＴＧＴＴＧ−３’（配列番号１１）
５’−ＧＡＡＧＧＣＴＴＣＡＴＡＧＴＣＣＡＧＣＡＧＡＴＣ−３’（配列番号１２）
相対比を算出するための標準遺伝子にはＧｌｙｃｅｒａｌｄｅｈｙｄｅ−３−ｐｈｏｓｐｈａｔｅ ｄｅｈｙｄｒｏｇｅｎａｓｅ（ＧＡＰＤＨ）Ｃｏｎｔｒｏｌ Ｒｅａｇｅｎｔｓ（Ａｐｐｌｉｅｄ Ｂｉｏｓｙｓｔｅｍｓ）を用いてＧＡＰＤＨの発現量を求め、相対比を算出した。
＜生細胞数の測定＞
ｓｉＲＮＡ導入後の生細胞数をＡｌａｍａｒ Ｂｌｕｅ（Ｂｉｏｓｏｕｒｃｅ）を用いて、添付のプロトコールに従い、Ｗａｌｌａｃ １４２０ Ｍｕｌｔｉｌａｂｅｌ／Ｌｕｍｉｎｅｓｃｅｎｃｅ Ｃｏｕｎｔｅｒ ＡＲＶＯ（ＰｅｒｋｉｎＥｌｍｅｒ）により測定した。
結果
大腸がん由来の細胞株であるＲＫＯＥ６を用いて、ＭＯＣＳ３遺伝子のＲＮＡｉ解析を実施した。
図２に、ＲＫＯＥ６細胞にＭＯＣＳ３遺伝子のｓｉＲＮＡをＴｒａｎｓｆｅｃｔｉｏｎ後、４日目の観察像を示す（上段：×４０；下段：×２００）。ａ，ｂ，およびｃは、それぞれＭＯＣＳ３遺伝子のｓｉＲＮＡ３種であり、ＮＣはネガティブコントロールを示す。示されるように、表現型の観察では、ａ、ｂ、およびｃ３種類のｓｉＲＮＡ共にＮｅｇａｔｉｖｅ Ｃｏｎｔｒｏｌ（ＮＣ）と比較して顕著に細胞数が減少していた（図２）。
図３には、ＲＫＯＥ６細胞にＭＯＣＳ３遺伝子のｓｉＲＮＡをＴｒａｎｓｆｅｃｔｉｏｎして２４時間後に細胞を回収し、定量的ＲＴ−ＰＣＲを行った結果を示す。内在性コントロールとして、ＧＡＰＤＨの相対比を用いて、ＮＣに対する相対量を示した。示されるように、ＲＮＡレベルでの効果を定量的ＲＴ−ＰＣＲで確認した結果、三種類のｓｉＲＮＡ共に顕著に発現量が減少していた（図３）。
図４には、ＲＫＯＥ６細胞にＭＯＣＳ３遺伝子のｓｉＲＮＡをＴｒａｎｓｆｅｃｔｉｏｎ後、４日目の細胞を用いて測定試薬により生細胞数を測定した結果を示す。グラフはＮＣに対する相対量を示した。示されるように、生細胞数の測定を行った結果、表現型同様、Ｎｅｇａｔｉｖｅ Ｃｏｎｔｒｏｌ（ＮＣ）と比較して顕著に細胞数が減少していた（図４）。ＭＯＣＳ３遺伝子のｓｉＲＮＡ３種（ａ，ｂ，ｃ）全てについて、ｔ検定において有意（ｐ＜０．０１）であった。
よって、ＲＮＡｉ効果によりＭＯＣＳ３遺伝子の発現が抑制された結果、ＲＫＯＥ６において、顕著にがん細胞の増殖が抑制されることが見出された。
実施例４：大腸由来正常細胞株を用いたＲＮＡｉ解析による機能解析
本実施例では、大腸の正常組織由来の細胞株を用いてＲＮＡｉ解析を実施することにより、標的遺伝子の抑制効果ががん特異的であることを検証した。
＜ＲＮＡｉ解析＞
細胞株はＡＴＣＣより購入したＣＣＤ１８Ｃｏを使用した。培養条件は、添付のプロトコールに従った。使用したｓｉＲＮＡは、実施例３のａ配列を使用した。ｓｉＲＮＡの細胞内への導入は、Ｌｉｐｏｆｅｃｔａｍｉｎｅ ２０００（Ｉｎｖｉｔｒｏｇｅｎ）を使用し、２５ｎＭのｓｉＲＮＡを添付のプロトコールに従い細胞に導入した。対照にはＮｅｇａｔｉｖｅ Ｃｏｎｔｒｏｌ ｓｉＲＮＡ（ＱＩＡＧＥＮ）を使用した。導入後５日間、倒立顕微鏡下で観察した。
＜定量的ＲＴ−ＰＣＲ解析＞
実施例３の記載方法と同様に実施した。
＜生細胞数の測定＞
実施例３の記載方法と同様に実施した。
結果
ＭＯＣＳ３遺伝子の、大腸正常組織由来の細胞株ＣＣＤ１８ＣｏでのＲＮＡｉの効果は以下の通りである。
図５に、ＣＣＤ１８Ｃｏ細胞にＭＯＣＳ３遺伝子のｓｉＲＮＡをＴｒａｎｓｆｅｃｔｉｏｎ後、５日目に得た観察像を示す（上段：×４０；下段：×２００）。ａ，ｂ，およびｃは、ＭＯＣＳ３遺伝子のｓｉＲＮＡ３種であり、ＮＣはネガティブコントロールを示す。示されるように、表現型の観察では、ＮＣとほぼ同様で、効果は認められなかった（図５）。
図６に、ＣＣＤ１８Ｃｏ細胞にＭＯＣＳ３遺伝子のｓｉＲＮＡをＴｒａｎｓｆｅｃｔｉｏｎして２４時間後に細胞を回収し、定量的ＲＴ−ＰＣＲを行った結果を示す。内在性コントロールとして、ＧＡＰＤＨの相対比を用いて、ＮＣに対する相対量を示した。ＲＮＡレベルでの効果を定量的ＲＴ−ＰＣＲで確認した結果、発現量の低下が認められた（図６）。
図７に、ＣＣＤ１８Ｃｏ細胞にＭＯＣＳ３遺伝子のｓｉＲＮＡをＴｒａｎｓｆｅｃｔｉｏｎ後、５日目の細胞を用いて測定試薬により生細胞数を測定した結果を示す。グラフはＮＣに対する相対量を示す。その結果、表現型同様、Ｎｅｇａｔｉｖｅ Ｃｏｎｔｒｏｌ（ＮＣ）とほぼ同様で、効果は認められなかった（図７）。
このことにより、大腸がん由来の細胞株であるＲＫＯＥ６では、ＲＮＡｉ効果によりＭＯＣＳ３遺伝子の発現が抑制された結果、顕著にがん細胞の増殖が抑制されたが、大腸正常組織由来の細胞株ＣＣＤ１８Ｃｏでは影響が無いことが見出された。よって、ＭＯＣＳ３遺伝子が、正常細胞には影響が少ないことより、がん特異的な創薬標的遺伝子となりうることを見出した。
実施例５：臓器特異性の評価
ＭＯＣＳ３遺伝子が正常組織でどのような臓器特異的な発現がされているのか、当該技術分野で公知のノーザンハイブリダイゼーション法により、実施した。
ＭＴＮ Ｍｕｌｔｉｐｌｅ Ｔｉｓｓｕｅ Ｎｏｒｔｈｅｒｎ Ｂｌｏｔｓ（Ｃｌｏｎｔｅｃｈ）を用いて、添付のプロトコールに従い、１０６ｂｐ（ＮＭ＿０１４４８４：３５−１４０）のＤＮＡ Ｐｒｏｂｅでハイブリダイゼーションを実施した。
結果
正常な各臓器組織でのＲＮＡレベルの発現分布について、２３種の臓器（心臓（Ｈｅａｒｔ）、脳（Ｂｒａｉｎ）、胎盤（Ｐｌａｃｅｎｔａ）、肺（Ｌｕｎｇ）、肝臓（Ｌｉｖｅｒ）、骨格筋（Ｓｋｅｌｅｔａｌ Ｍｕｓｃｌｅ）、腎臓（Ｋｉｄｎｅｙ）、膵臓（Ｐａｎｃｒｅａｓ）、脾臓（Ｓｐｌｅｅｎ）、胸腺（Ｔｈｙｍｕｓ）、前立腺（Ｐｒｏｓｔａｔｅ）、睾丸（Ｔｅｓｔｉｓ）、卵巣（Ｏｖａｒｙ）、小腸（Ｓｍａｌｌ Ｉｎｔｅｓｔｉｎｅ）、結腸（Ｃｏｌｏｎ）、末梢血白血球（Ｐｅｒｉｐｈｅｒａｌ Ｂｌｏｏｄ Ｌｅｕｋｏｃｙｔｅ）、胃（Ｓｔｏｍａｃｈ）、甲状腺（Ｔｈｙｒｏｉｄ）、脊髄（Ｓｐｉｎａｌ Ｃｏｒｄ）、リンパ節（Ｌｙｍｐｈ Ｎｏｄｅ）、気管（Ｔｒａｃｈｅａ）、副腎（Ａｄｒｅｎａｌ Ｇｌａｎｄ）、骨髄（Ｂｏｎｅ Ｍａｒｒｏｗ））についてノーザンハイブリダイゼーション法により、解析した。なお、前述のとおり、ＭＯＣＳ３の遺伝子配列は、ＮＣＢＩ（ｈｔｔｐ：／／ｗｗｗ．ｎｃｂｉ．ｎｌｍ．ｎｉｈ．ｇｏｖ）に、Ａｃｃｅｓｓｉｏｎ Ｎｏ．ＮＭ＿０１４４８４で２，４５８ｂｐの配列がｍＲＮＡとして登録されている。
図８は、正常な種々の臓器組織を用いて行ったノーザンハイブリダイゼーションの結果を示す写真である。図に示すように、精巣において約２．５ｋｂ付近にバンドが認められ、他の臓器については、発現量が少ないことが確認された。正常組織において発現量が少なく、精巣特異的であることは、この遺伝子を標的にした薬剤の影響が正常組織に対して少ないことが推定できる。
実施例６：遺伝子増幅の評価
ＭＯＣＳ３遺伝子が検体組織内のがん細胞で遺伝子増幅が起きていることを、当該技術分野で公知のＦＩＳＨ（ｆｌｕｏｒｅｓｃｅｎｃｅ ｉｎ ｓｉｔｕ ｈｙｂｒｉｄｉｚａｔｉｏｎ）法により実施した。
アレイＣＧＨ法により、遺伝子増幅度（Ｇ／Ｒ）が１．２以上であった検体組織（大腸癌患者由来）を用いて、ＭＯＣＳ３遺伝子が位置するＢＡＣ Ｃｌｏｎｅ ＲＰ１１−３７９Ｄ４のＤＮＡ Ｐｒｏｂｅでハイブリダイゼーションを実施した。
検体組織のがん細胞においてＭＯＣＳ３遺伝子領域で遺伝子増幅がおきていることをＦＩＳＨ法により評価した。
結果
図９は、観察したがん細胞の一部（６細胞分）の光学顕微鏡写真（蛍光像）である。示されるように、がん細胞においてシグナルが３スポット以上見出された。アレイＣＧＨ法により遺伝子増幅度（Ｇ／Ｒ）が１．２以上であった１０検体において、ＭＯＣＳ３遺伝子領域が増幅していることが確認された。また、病態ステージの初期から後期にわたり遺伝子増幅が起きていることが示された。このことは、ＭＯＣＳ３遺伝子領域が、がん治療薬の分子標的としてだけでなく、ＦＩＳＨ法によるがん診断に応用できることを示している。
実施例７：がん特異性の評価
ＭＯＣＳ３遺伝子が、がん検体組織で発現していることを、当該技術分野で公知の免疫染色法により実施した。
アレイＣＧＨ法により、遺伝子増幅度（Ｇ／Ｒ）が１．２以上であった検体組織（大腸癌患者由来）を用いて、抗ＭＯＣＳ３遺伝子ポリクローナル抗体で免疫組織染色法を実施した。
結果
図１０は、検体組織のがん細胞においてＭＯＣＳ３遺伝子のタンパク質が発現していることを免疫組織染色法で評価した結果を示す。図に示されるように、がん部特異的に発現していることが確認された。低分化腺がん部の、複数の核が重なり構造が不規則な上皮細胞で染色が認められた。一方、細胞が秩序良く整列した、粘膜固有層や正常な腸腺部での染色は、認められなかった。
アレイＣＧＨ法により遺伝子増幅度（Ｇ／Ｒ）が１．２以上であった１０検体の内、１０検体のがん部でＭＯＣＳ３遺伝子の発現が確認され、遺伝子増幅が起きている検体において、高頻度に発現が亢進していることが示された。
また、病態ステージの初期から後期にわたり発現が亢進していることが示された。このことは、ＭＯＣＳ３遺伝子領域が、がん治療薬の分子標的としてだけでなく、がん診断に応用できることを示している。
実施例８：子宮頸がん細胞株ＨｅＬａ細胞株でのＲＮＡｉ効果の評価
大腸がん細胞株ではＭＯＣＳ３遺伝子のノックダウンにより、増殖抑制効果が認められたが、子宮頸がん細胞株においてどのような効果が認められるのか、前述のＲＮＡｉ解析法により、評価した。
子宮頸がん細胞であるＨｅＬａ細胞株を用いて、前出の３種のｓｉＲＮＡ（実施例３：表５）を用いて実施例３の記載方法と同様にＲＮＡｉ解析を実施した。ｓｉＲＮＡの細胞内への導入は、Ｏｌｉｇｏｆｅｃｔａｍｉｎｅ（Ｉｎｖｉｔｒｏｇｅｎ）を使用し、１００ｎＭのｓｉＲＮＡを添付のプロトコールに従い細胞に導入した。対照にはＮｅｇａｔｉｖｅ Ｃｏｎｔｒｏｌ ｓｉＲＮＡ（ＱＩＡＧＥＮ）を使用した。
結果
図１１は、ＨｅＬａ細胞にＭＯＣＳ３遺伝子のｓｉＲＮＡをＴｒａｎｓｆｅｃｔｉｏｎ後、４日目の細胞を用いて測定試薬により生細胞数を測定した結果を示す。グラフはＮＣに対する相対量を示した。図に示されるように、ＭＯＣＳ３遺伝子のｓｉＲＮＡ３種（ａ，ｂ，ｃ）の内、ｓｉＲＮＡ ｂにおいて１５％、ｓｉＲＮＡ ｃにおいて２５％の増殖抑制効果が認められた（ｐ＜０．０１のｔ検定において有意）。
さらに、時系列に従い、顕微鏡下で微分干渉像を撮影し、その動態を詳細に観察した。その結果を、図１２に示す。図中、ａ、ｂ、およびｃはそれぞれ、図１１のｓｉＲＮＡａ、ｓｉＲＮＡｂ、およびｓｉＲＮＡｃに対応する。図１２に示されるように、増殖抑制が認められたｂ、ｃにおいて細胞死の誘導が認められた。（３日後のｂ、ｃにおいて、死細胞を赤点で示した。）
この結果よりＭＯＣＳ３遺伝子機能の阻害が大腸がんだけでなく、子宮頸がんにおいても抗腫瘍性効果を示すことが示唆された。
実施例９：質量分析による血中ＭＯＣＳ３タンパク質の検出
１）血液検体の前処理
大腸癌患者の血清検体１０μＬ及び健常者血清検体１０μＬを、希釈バッファ溶液（１０ｍＭ Ｔｒｉｓ ＨＣｌ ｐｈ７．４＋１５０ｍＭ ＮａＣｌ）５００μＬで希釈後、ＰｒｏｔｅｏｍｅＬａｂ ＩｇＹ−１２ ＳＣ プロテオームパーティショニングキット（ＢＥＣＫＭＡＮ ＣＯＵＬＴＥＲ：Ａ２４６１８）を用いてアルブミン、グロブリン等の血清中多量蛋白質を除去した。得られた画分に終濃度１０ｍＭとなるようにジチオスレイトール（Ｗａｋｏ：０４９−０８９７２）を加え、還元反応を６０℃で３０分間行った。反応終了後、終濃度１０ｍＭとなるようにヨードアセトアミド（ＳＩＧＭＡ：１４４−４８−９）を加え、アルキル化反応を室温で３０分間、遮光状態で行った。反応終了後、反応液の４倍量の冷アセトン（Ｗａｋｏ：０１４−０８６８１，−２０℃）を加え、−８０℃に１時間静置した後に１５，０００ｘｇで３０分間遠心してタンパク質を沈殿として回収した。回収したタンパク質は８０μＬの２Ｍ尿素＋１００ｍＭ重炭酸アンモニウム溶液に溶解した。溶解後に一部をＢＣＡ法によるタンパク質濃度測定に供した。試料タンパク質と１／５０（ｗ／ｗ）となるようにトリプシン（Ｐｒｏｍｅｇａ：Ｖ５１１Ｃ）を加え、３７℃で１６時間消化反応を行った。
２）Ｎａｎｏ−ＨＰＬＣ直結質量分析装置による解析
ペプチド断片０．７μｇ量をμ−Ｐｒｅｃｏｌｕｍｎ ｃａｒｔｒｉｄｇｅ（Ｃ１８ ＰｅｐＭａｐ３００，５μｍ，３００Å，３００μｍ ｉ．ｄ．ｘ５ｍｍ ＬＣ ＰＡＣＫＩＮＧＳ：１６３５８９）と直結させたナノカラム（Ｃ１８ ＰｅｐＭａｐ ３μｍ，１００Å，７５μｍ ｉ．ｄ．ｘ１５０ｍｍ ＬＣ ＰＡＣＫＩＮＧＳ：１６０３２１）により分離した。ＨＰＬＣ装置はＵｌｔｉｍａｔｅ Ｐｌｕｓ（ＬＣ ＰＡＣＫＩＮＧＳ）を用いた。流速は２００ｎＬ／ｍｉｎ、０．１％ギ酸（Ｗａｋｏ：０６２−０２９０１）含有２％アセトニトリル（ＭＥＲＣＫ：１２８７２２９）と０．１％ギ酸含有９０％アセトニトリルの濃度勾配が０．５７％／ｍｉｎの直線グラジエントを設定して解析を行った。Ｎａｎｏ−ＨＰＬＣで分離した試料はＰｉｃｏＴｉｐ（Ｎｅｗ Ｏｂｊｅｃｔｉｖｅ：ＦＳ３６０−２０−１０−Ｄ−２０）を通して直結したイオントラップ型質量分析装置に連続的に導入した。質量分析装置はＨＣＴ Ｐｌｕｓ（Ｂｒｕｋｅｒ Ｄａｌｔｏｎｉｃｓ）を用いた。試料のイオン化はキャピラリー電圧１５００Ｖ、エンドプレートオフセット値５００Ｖ、ドライガス流量１２Ｌ／ｍｉｎ、ドライガス温度２５０℃の条件で行った。イオントラップの設定は標的ｍ／ｚの前後２Ｄａの取り込みとし、ＭＲＭモードでのＭＳ／ＭＳ解析を行った。
３）データ解析
質量分析装置から得た全分析データはＤａｔａ Ａｎａｌｙｓｉｓソフトウエア（Ｂｒｕｋｅｒ Ｄａｌｔｏｎｉｃｓ）を介して出力した。出力した全データ中から標的分子の分析データのみを抽出した。抽出したデータの中から各分析時間におけるＭＳ／ＭＳデータを精査し、標的分子のフラグメントイオンに相当する質量を持つイオンピークの有無を解析した。
結果
図１３ＡおよびＢは、（Ａ）大腸がん患者由来の血清および（Ｂ）健常者由来の血清について、上記の方法で解析した結果をそれぞれ示す。
図１４Ａ〜Ｃは、ＭＳ／ＭＳ解析によって決定された、図１３に示すピークとアミノ酸（またはアミノ酸配列）との対応関係を示す。
図１３および１４に示されるように、標的分子のフラグメントイオンに相当するイオンピークが、大腸がん患者由来の血清中に明確に認められた。すなわち、図１４Ｂに示すように、少なくともＣ末端側からＥＰＳＬＬＱという部分配列が決定され、これは、ＭＯＣＳ３タンパク質のアミノ酸配列（配列番号２）中の、３２８位〜３３３位のアミノ酸配列に相当することから、アミノ酸配列３２６位〜３３５位の標的ペプチドフラグメント（配列番号１３）が同定された。このような部分配列に対応するイオンピークは健常者血清を用いた解析では認められなかった（図１４Ｃを参照）。よって、この標的分子（すなわち、ＭＯＣＳ３タンパク質）は癌特異的に血中存在量が増加している可能性が強く示唆された。
実施例１０：種々のがん種における特異性の評価
ＭＯＣＳ３遺伝子が、大腸がん以外の臓器癌で発現しているかどうかについて、当該技術分野で公知の免疫染色法により実施した。
３５種類の臓器の癌組織が９６サンプル配置された、Ｍｕｌｔｉｐｌｅ ｏｒｇａｎ ｃａｎｃｅｒ ｔｉｓｓｕｅ ｍｉｃｒｏａｒｒａｙ ｆｏｒ ｔｅｓｔｉｎｇ ｔｕｍｏｒ ｔｉｓｓｕｅ ｓｐｅｃｉｆｉｃｉｔｙ ｏｆ ｔｈｅｒａｐｅｕｔｉｃ ａｎｔｉｂｏｄｉｅｓ（ＵＳ Ｂｉｏｍａｘ社）を用いて、抗ＭＯＣＳ３遺伝子ポリクローナル抗体で免疫組織染色法を実施した。
免疫組織染色法は、賦活化方法についてはＹａｍａｓｈｉｔａ Ｓ ＆ Ｏｋａｄａ Ｙ．（２００５）Ｊ Ｈｉｓｔｏｃｈｅｍ Ｃｙｔｏｃｈｅｍ．Ｎｏｖ；５３（１１）：１４２１−３２に、染色方法については、渡辺・中野 酵素抗体法 改訂四版（学際企画）に準じた。
ネガティブコントロールにウサギＩｇＧを使用した。
結果
３５種類の臓器（脳、食道、胃、肝、小腸、結腸、直腸、膵、網膜、肺、子宮頚部、子宮、乳、卵巣、脾、前立腺、精巣、腎、膀胱、リンパ節、縦隔、腸間膜、骨組織、喉頭軟骨、頬、唇、鼻、咽喉、喉頭、咽頭、舌、脂肪組織、線維組織、甲状腺、皮膚）のがん組織についてＭＯＣＳ３タンパク質の発現を免疫組織染色法で解析し、いくつかのがん種において特異的な発現が認められた。その結果を図１５−１および図１５−２に示す。
図１５−１および図１５−２は、解析した臓器の内、発現が認められた胃（Ａ：ｓｔｏｍａｃｈ）、結腸（Ｂ：ｃｏｌｏｎ）、直腸（Ｃ：ｒｅｃｔｕｍ）、網膜（Ｄ：ｅｐｉｐｌｏｏｎ）、肺（Ｅ、Ｆ、Ｇ：ｌｕｎｇ）、卵巣（Ｉ、Ｊ：ｏｖａｒｙ）、前立腺（Ｌ：ｐｒｏｓｔａｔｅ）、リンパ節（Ｍ：Ｌｙｍｐ ｎｏｄｅ）、骨組織（Ｏ：ｂｏｎｅ）、および縦隔（Ｒ：ｍｅｄｉａｓｔｉｎｕｍ）における結果を示す。また、弱いながらも、乳（Ｈ：ｂｒｅａｓｔ）、脾臓（Ｋ：ｓｐｌｅｅｎ）、咽喉（Ｐ：ｔｈｒｏａｔ）、および脂肪組織（Ｑ：ｆａｔｔｙ ｔｉｓｓｕｅ）においても発現が認められた。
傾向としてリンパ腫において比較的顕著な発現が認められた（図１５−１Ｂ、図１５−２Ｋ、Ｍ、Ｎ、およびＲ）。また、ＭＯＣＳ３は腺腫において発現が認められた（図１５−１Ａ、Ｃ、Ｄ、Ｉ、Ｊ、および図１５−２Ｌ）。
これにより、ＭＯＣＳ３が幅広いがん種で発現が亢進していることが示された。このことは、ＭＯＣＳ３が、がん治療薬の分子標的としてのがん特異性が示されたと同時に、大腸がんだけではなく、幅広いがん種に対しての適用が可能であることが示唆された。これは、がん診断への応用においても同様であり、ＭＯＣＳ３の重大な有効性を示唆している。 Example 1: Identification of colon cancer-specific amplification gene by array CGH method In this example, in order to identify a gene amplification region specific for colon cancer, sample preparation of 200 cases of colon cancer specimen and array CGH method Based on the verification.
As a result, gene information in the public DB (NCBI: http://www.ncbi.nlm.nih.gov/) was used for examination in a region where amplification frequently occurred in colorectal cancer specimens. As a result, it was found that the MOCS3 (Molybdenum factor synthesis 3) (NCBI Accession No .: NM — 014484) gene located in the used BAC Clone RPll-379D4 has a high value in colorectal cancer patients (FIG. 1). , Table 2). FIG. 1 is a histogram showing the frequency of the MOCS3 gene relative to the degree of amplification in 200 colorectal cancer patients. Table 2 below shows the degree of amplification (G / R value) and frequency of 200 MOCS3 gene colon cancer patients. The average value indicates an average value of specimens having a G / R value of 1.2 or more.
As shown in Table 2, the MOCS3 gene was amplified in 68.5% of 200 colorectal cancer patients, and the average value of the amplification degree was 1.73. The maximum value was 3.09, and remarkable amplification occurred very frequently.

Example 2: Verification of the degree of gene amplification in a colon-derived cultured cell line In this example, the degree of amplification in a colon cancer-derived cultured cell line was verified for a high-frequency and high-value gene region in colon cancer patients.
<Sample preparation>
The cultured cell line used was RKOE6, Caco2, which is a cell line derived from colorectal cancer. Genomic DNA was extracted from cultured cells using Blood & Cell Culture DNA Kit (QIAGEN) according to the protocol attached to the kit.
<Array CGH>
In order to confirm the amplification of the gene region, an array CGH was performed. Details of the method were carried out in the same manner as in Example 1.
Results Table 3 shows the degree of amplification (G / R value) of the MOCS3 gene in a colon cancer-derived cell line. As shown, it was found that amplification occurred in the MOCS3 gene located in BAC Clone RP11-379D4 also in the colon cancer-derived cell line.

<Quantitative PCR>
Quantitative PCR was performed to confirm the amplification of the MOCS3 gene region. Quantitative PCR was performed using SYBR Green RT-PCR Reagents (Applied Biosystems) and 7500 Real-Time PCR System (Applied Biosystems) according to the attached protocol. The primers used were the following sequences synthesized (commissioned to OPERON).
Primer sequence:
5′-CCTCTTACAGTGGCAGCTTGTG-3 ′ (SEQ ID NO: 3)
5′-GAAGGCTTCATAGTCCCAGCAGATC-3 ′ (SEQ ID NO: 4)
Results Table 4 shows the degree of amplification of the MOCS3 gene in a colon cancer-derived cell line. Values are relative to control DNA (normal). As shown, it was found that amplification occurred in the MOCS3 gene region also in the colon cancer-derived cell line.

From these results, it was confirmed that the MOCS3 gene was also amplified in a colon cancer-derived cell line (RKOE6, Caco2). Therefore, cultured cells that can be used for functional analysis of the MOCS3 gene in cancer were selected.
Example 3: Functional analysis by RNAi analysis using a colorectal cancer cell line In this example, the MOCS3 gene, which was frequently amplified in 200 colorectal cancer patients, was a colorectal cancer-derived cell line. Furthermore, RNAi analysis was performed using a cell line (RKOE6) in which gene amplification was observed at the genome level, and the phenotype was observed.
<RNAi analysis>
Cell lines were purchased from ATCC and cultured according to the attached protocol. For siRNA, a specific 21mer in the gene was selected and siRNA targeting the sequence was synthesized (commissioned to QIAGEN).

For siRNA introduction into RKOE6 cells, Oligofectamine (Invitrogen) was used, and 100 nM siRNA was introduced into the cells according to the attached protocol. As a control, Negative Control siRNA (QIAGEN) was used. The cells were observed under an inverted microscope for 4 days after introduction into the cells.
<Quantitative RT-PCR analysis>
The effect of siRNA was verified at the mRNA level using a quantitative RT-PCR method. Total RNA was extracted from the cells 24 hours after the introduction of siRNA using a Micro-to-Midi Total RNA Purification System (Invitrogen) according to the attached protocol. Subsequently, cDNA was synthesized using SuperScript III First-Strand Synthesis System for RT-PCR (Invitrogen) according to the attached protocol.
Quantitative RT-PCR was performed using this cDNA as a template. Quantitative PCR was performed using SYBR Green RT-PCR Reagents (Applied Biosystems) and 7500 Real-Time PCR System (Applied Biosystems) according to the attached protocol. The primers used were the following sequences synthesized (commissioned to OPERON).
Primer sequence:
5′-CCTCTTACAGTGGCAGCTTGTG-3 ′ (SEQ ID NO: 11)
5′-GAAGGCTTCATAGTCCCAGCAGATC-3 ′ (SEQ ID NO: 12)
As a standard gene for calculating the relative ratio, the expression level of GAPDH was obtained using Glyceraldehyde-3 phosphate dehydrogenase (GAPDH) Control Reagents (Applied Biosystems), and the relative ratio was calculated.
<Measurement of the number of living cells>
The number of viable cells after introduction of siRNA was measured by Wallac 1420 Multilabel / Luminescence Counter ARVO (PerkinElmer) using Alamar Blue (Biosource) according to the attached protocol.
Results RNAi analysis of the MOCS3 gene was performed using RKOE6, a cell line derived from colon cancer.
FIG. 2 shows observation images on day 4 after transfection with siRNA of MOCS3 gene in RKOE6 cells (upper row: × 40; lower row: × 200). a, b, and c are 3 types of siRNAs of the MOCS3 gene, and NC indicates a negative control. As shown, in the phenotypic observation, the number of cells of a, b, and c3 types of siRNAs was significantly reduced as compared with the negative control (NC) (FIG. 2).
FIG. 3 shows the result of quantitative RT-PCR after 24 hours after siRNA of MOCS3 gene was tranfected into RKOE6 cells. As an endogenous control, the relative amount of NC was shown using the relative ratio of GAPDH. As shown, as a result of confirming the effect at the RNA level by quantitative RT-PCR, the expression level of all three types of siRNAs was significantly reduced (FIG. 3).
FIG. 4 shows the results of measuring the number of viable cells with the measuring reagent using the cells on the 4th day after transfecting siRNA of MOCS3 gene to RKOE6 cells. The graph showed the relative amount with respect to NC. As shown, as a result of measuring the number of living cells, the number of cells was remarkably reduced as compared with Negative Control (NC) as in the phenotype (FIG. 4). All three types of siRNA (a, b, c) of the MOCS3 gene were significant (p <0.01) in the t-test.
Therefore, as a result of suppressing the expression of the MOCS3 gene by the RNAi effect, it was found that the growth of cancer cells was remarkably suppressed in RKOE6.
Example 4: Functional analysis by RNAi analysis using a normal cell line derived from the large intestine In this example, by performing RNAi analysis using a cell line derived from a normal tissue of the large intestine, the suppression effect of the target gene is cancer-specific. We verified that it was appropriate.
<RNAi analysis>
The cell line used was CCD18Co purchased from ATCC. The culture conditions followed the attached protocol. As the siRNA used, the a sequence of Example 3 was used. For introduction of siRNA into cells, Lipofectamine 2000 (Invitrogen) was used, and 25 nM siRNA was introduced into the cells according to the attached protocol. As a control, Negative Control siRNA (QIAGEN) was used. It observed under the inverted microscope for 5 days after introduction | transduction.
<Quantitative RT-PCR analysis>
The same procedure as described in Example 3 was performed.
<Measurement of the number of living cells>
The same procedure as described in Example 3 was performed.
Results The effect of RNAi on the cell line CCD18Co derived from normal colon tissue of the MOCS3 gene is as follows.
FIG. 5 shows an observation image obtained on the fifth day after the siRNA of the MOCS3 gene was tranfected into CCD18Co cells (upper: x40; lower: x200). a, b, and c are 3 types of siRNAs of the MOCS3 gene, and NC represents a negative control. As shown, observation of the phenotype was almost the same as NC and no effect was observed (FIG. 5).
FIG. 6 shows the result of quantitative RT-PCR after 24 hours after the siRNA of MOCS3 gene was tranfected into CCD18Co cells and the cells were collected. As an endogenous control, the relative amount of NC was shown using the relative ratio of GAPDH. As a result of confirming the effect at the RNA level by quantitative RT-PCR, a decrease in the expression level was observed (FIG. 6).
FIG. 7 shows the results of measuring the number of viable cells with the measurement reagent using the cells on the fifth day after the siRNA of MOCS3 gene was tranfected into CCD18Co cells. The graph shows the relative amount with respect to NC. As a result, like the phenotype, it was almost the same as Negative Control (NC), and no effect was observed (FIG. 7).
As a result, in RKOE6, which is a cell line derived from colorectal cancer, the expression of the MOCS3 gene was suppressed by the RNAi effect. As a result, the growth of cancer cells was remarkably suppressed, but the cell line CCD18Co derived from normal colon tissue Was found to have no effect. Therefore, the present inventors have found that the MOCS3 gene can be a cancer-specific drug target gene because it has less influence on normal cells.
Example 5: Evaluation of organ specificity The organ-specific expression of the MOCS3 gene in normal tissues was determined by a Northern hybridization method known in the art.
Hybridization was performed with 106 bp (NM — 014484: 35-140) DNA Probe according to the attached protocol using MTN Multiple Tissue Northern Blots (Clontech).
Results Regarding the expression distribution of RNA levels in normal organ tissues, 23 kinds of organs (Heart, Brain, Placenta, Lung, Liver, Liver, Skeletal Muscle) ), Kidney, Pancreas, Spleen, Thymus, Prostate, Testis, Ovary, Small Intestine, Colon, Peripheral blood White blood cells (Peripheral Blood Leukocyte), stomach (Stormach), thyroid (Thyroid), spinal cord (Spinal Cord), lymph node (Lymph Node), trachea (Trachea), adrenal gland (Adrenal Gland) , Bone marrow) was analyzed by Northern hybridization. As described above, the gene sequence of MOCS3 is NCBI (http://www.ncbi.nlm.nih.gov) and Accession No. In NM_014484, a 2,458 bp sequence is registered as mRNA.
FIG. 8 is a photograph showing the results of Northern hybridization performed using various normal organ tissues. As shown in the figure, a band was observed near about 2.5 kb in the testis, and it was confirmed that the expression level of other organs was small. It can be presumed that the expression level in normal tissues is small and testis-specific is less affected by drugs targeting this gene.
Example 6: Evaluation of gene amplification It was carried out by FISH (fluorescence in situ hybridization) method known in the art that gene amplification occurred in cancer cells in the specimen tissue of the MOCS3 gene.
Using a sample tissue (derived from a colon cancer patient) having a gene amplification degree (G / R) of 1.2 or more by the array CGH method, hybridization was performed with a DNA probe of BAC Clone RP11-379D4 in which the MOCS3 gene is located. Carried out.
It was evaluated by the FISH method that gene amplification occurred in the MOCS3 gene region in the cancer cells of the specimen tissue.
Results FIG. 9 is an optical micrograph (fluorescence image) of part of the observed cancer cells (for 6 cells). As shown, more than 3 spots of signal were found in cancer cells. It was confirmed by the array CGH method that the MOCS3 gene region was amplified in 10 samples having a gene amplification degree (G / R) of 1.2 or more. It was also shown that gene amplification occurred from the early stage to the late stage of the disease state. This indicates that the MOCS3 gene region can be applied not only as a molecular target for cancer therapeutic agents but also for cancer diagnosis by the FISH method.
Example 7: Evaluation of cancer specificity The fact that the MOCS3 gene is expressed in cancer specimen tissues was determined by an immunostaining method known in the art.
By the array CGH method, an immunohistochemical staining method was performed with an anti-MOCS3 gene polyclonal antibody using a sample tissue (derived from a colon cancer patient) having a gene amplification degree (G / R) of 1.2 or more.
Results FIG. 10 shows the results of evaluation by immunohistochemical staining that the MOCS3 gene protein is expressed in cancer cells of the specimen tissue. As shown in the figure, it was confirmed that the tumor was specifically expressed. In the poorly differentiated adenocarcinoma, multiple nuclei overlapped and the epithelial cells with irregular structure were stained. On the other hand, there was no staining in the lamina propria or normal intestinal gland where the cells were well-ordered.
Among 10 specimens whose gene amplification degree (G / R) was 1.2 or more by the array CGH method, the expression of MOCS3 gene was confirmed in 10 cancerous parts, and in the specimen where gene amplification occurred, It was shown that the expression increased with frequency.
It was also shown that the expression was increased from the early stage to the late stage of the pathological stage. This indicates that the MOCS3 gene region can be applied not only as a molecular target for cancer therapeutic agents but also for cancer diagnosis.
Example 8: Evaluation of RNAi effect in cervical cancer cell line HeLa cell line In the colon cancer cell line, the growth suppression effect was observed by knockdown of the MOCS3 gene. The above-mentioned RNAi analysis method was used to evaluate whether or not the effect was recognized.
Using the HeLa cell line, which is a cervical cancer cell, RNAi analysis was performed in the same manner as described in Example 3 using the three types of siRNA (Example 3: Table 5). For introduction of siRNA into cells, Oligofectamine (Invitrogen) was used, and 100 nM siRNA was introduced into the cells according to the attached protocol. As a control, Negative Control siRNA (QIAGEN) was used.
Results FIG. 11 shows the results of measuring the number of viable cells with the measuring reagent using the cells on the 4th day after transfecting siRNA of MOCS3 gene to HeLa cells. The graph showed the relative amount with respect to NC. As shown in the figure, among the 3 types of siRNAs (a, b, c) of the MOCS3 gene, 15% of the siRNA b and 25% of the siRNA c were found to have a growth inhibitory effect (t test of p <0.01). Significant).
Furthermore, according to the time series, differential interference images were taken under a microscope, and their dynamics were observed in detail. The result is shown in FIG. In the figure, a, b, and c correspond to siRNAa, siRNAb, and siRNAc in FIG. 11, respectively. As shown in FIG. 12, induction of cell death was observed in b and c where growth suppression was observed. (Dead cells are indicated by red dots in b and c after 3 days.)
This result suggests that inhibition of the MOCS3 gene function shows an antitumor effect not only in colorectal cancer but also in cervical cancer.
Example 9: Detection of blood MOCS3 protein by mass spectrometry 1) Pretreatment of blood sample 10 μL of serum sample of colon cancer patient and 10 μL of healthy subject serum sample are diluted with 500 μL of a diluted buffer solution (10 mM Tris HCl ph 7.4 + 150 mM NaCl). Thereafter, serum abundant proteins such as albumin and globulin were removed using a ProteomeLab IgY-12 SC proteome partitioning kit (BECKMAN COULTER: A24618). Dithiothreitol (Wako: 049-08972) was added to the obtained fraction to a final concentration of 10 mM, and the reduction reaction was performed at 60 ° C. for 30 minutes. After completion of the reaction, iodoacetamide (SIGMA: 144-48-9) was added to a final concentration of 10 mM, and the alkylation reaction was performed at room temperature for 30 minutes in a light-shielded state. After completion of the reaction, 4 times the amount of the reaction solution cold acetone (Wako: 014-08681, -20 ° C.) was added, left standing at −80 ° C. for 1 hour, and centrifuged at 15,000 × g for 30 minutes to recover the protein as a precipitate. did. The recovered protein was dissolved in 80 μL of 2M urea + 100 mM ammonium bicarbonate solution. After dissolution, a part was subjected to protein concentration measurement by the BCA method. Trypsin (Promega: V511C) was added so as to be 1/50 (w / w) with the sample protein, and digestion reaction was performed at 37 ° C. for 16 hours.
2) Analysis by Nano-HPLC direct coupled mass spectrometer Nanocolumn (C18 PepMap 3) directly coupled with 0.7-g peptide fragment with μ-Precolumn cartridge (C18 PepMap300, 5 μm, 300 μm, 300 μm id × 5 mm LC PACKINGS: 163589) , 100 μm, 75 μm id × 150 mm LC PACKINGS: 160321). As the HPLC apparatus, Ultimate Plus (LC PACKINGS) was used. The flow rate is 200 nL / min, a linear gradient with a concentration gradient of 0.57% / min between 2% acetonitrile (MERCK: 1287229) containing 0.1% formic acid (Wako: 062-2901) and 90% acetonitrile containing 0.1% formic acid. Was set for analysis. Samples separated by Nano-HPLC were continuously introduced into an ion trap type mass spectrometer directly connected through PicoTip (New Objective: FS360-20-10-D-20). As a mass spectrometer, HCT Plus (Bruker Daltonics) was used. The sample was ionized under the conditions of a capillary voltage of 1500 V, an end plate offset value of 500 V, a dry gas flow rate of 12 L / min, and a dry gas temperature of 250 ° C. The ion trap was set to capture 2 Da before and after the target m / z, and MS / MS analysis was performed in MRM mode.
3) Data analysis All analysis data obtained from the mass spectrometer was output via Data Analysis software (Bruker Daltonics). Only the analysis data of the target molecule was extracted from all the output data. From the extracted data, the MS / MS data at each analysis time was examined closely, and the presence or absence of an ion peak having a mass corresponding to the fragment ion of the target molecule was analyzed.
Results FIGS. 13A and 13B show the results of analysis of (A) serum derived from a colon cancer patient and (B) serum derived from a healthy person by the above method, respectively.
14A to 14C show the correspondence between the peak shown in FIG. 13 and amino acids (or amino acid sequences) determined by MS / MS analysis.
As shown in FIGS. 13 and 14, an ion peak corresponding to the fragment ion of the target molecule was clearly observed in the serum derived from a colon cancer patient. That is, as shown in FIG. 14B, a partial sequence called EPSLLQ is determined at least from the C-terminal side, and this corresponds to the amino acid sequence at positions 328 to 333 in the amino acid sequence of the MOCS3 protein (SEQ ID NO: 2). From the result, a target peptide fragment (SEQ ID NO: 13) having an amino acid sequence of positions 326 to 335 was identified. An ion peak corresponding to such a partial sequence was not observed in the analysis using healthy human serum (see FIG. 14C). Therefore, it was strongly suggested that this target molecule (that is, MOCS3 protein) might have increased blood abundance specifically in cancer.
Example 10: Evaluation of specificity in various cancer types Whether or not the MOCS3 gene is expressed in organ cancers other than colorectal cancer was determined by an immunostaining method known in the art.
The anti-CS 3 was used as an antibody with a multi-organ cancer tissue tissue testing for the tissue of the antigenic antibodies (US Biomax) using 96 samples of cancer tissues of 35 types of organs.
For the immunohistochemical staining method, Yamashita S & Okada Y. (2005) J Histochem Cytochem. Nov; 53 (11): 1421-32, and the staining method was in accordance with Watanabe / Nakano Enzyme Antibody Method Revised 4th Edition (interdisciplinary project).
Rabbit IgG was used as a negative control.
Results 35 types of organs (brain, esophagus, stomach, liver, small intestine, colon, rectum, pancreas, retina, lung, cervix, uterus, breast, ovary, spleen, prostate, testis, kidney, bladder, lymph node, mediastinum , Mesentery, bone tissue, laryngeal cartilage, cheek, lips, nose, throat, larynx, pharynx, tongue, adipose tissue, fibrous tissue, thyroid, skin) Analyzed, specific expression was observed in several cancer types. The results are shown in FIGS. 15-1 and 15-2.
FIG. 15-1 and FIG. 15-2 show a stomach (A: stomach), colon (B: colon), rectum (C: rectum), retina (D: epiplon) in which expression was observed among the analyzed organs. Lung (E, F, G: lung), ovary (I, J: ovary), prostate (L: prostate), lymph node (M: Lymp node), bone tissue (O: bone), and mediastinum (R: The results in mediatinum) are shown. Although weak, expression was also observed in milk (H: breast), spleen (K: splene), throat (P: throat), and adipose tissue (Q: fatty tissue).
As a trend, relatively significant expression was observed in lymphomas (FIGS. 15-1B, 15-2K, M, N, and R). In addition, expression of MOCS3 was observed in adenomas (FIGS. 15-1A, C, D, I, J, and FIG. 15-2L).
Thereby, it was shown that the expression of MOCS3 is enhanced in a wide range of cancer types. This suggests that MOCS3 can be applied not only to colorectal cancer but also to a wide range of cancer types, as well as showing cancer specificity as a molecular target for cancer therapeutics. It was. This is the same in application to cancer diagnosis, suggesting the significant effectiveness of MOCS3.

The present invention provides cancer therapeutic agents, diagnostic agents, diagnostic methods, therapeutic methods, kits used therein, and the like. Therefore, the present invention is useful in fields such as cancer diagnosis and targeted therapy.
[Sequence Listing]

Claims (26)

A cancer therapeutic agent comprising a MOCS3 gene expression inhibitor as an active ingredient. The MOCS3 gene expression inhibitor is
(A) a nucleic acid having an action of inhibiting the expression of the MOCS3 gene by the RNAi effect,
(B) an antisense nucleic acid for the transcription product of MOCS3 gene or a part thereof,
And (c) a nucleic acid having ribozyme activity that specifically cleaves the transcript of the MOCS3 gene,
The cancer therapeutic agent of Claim 1 containing the substance selected from the group which consists of. A cancer therapeutic agent comprising an activity inhibitor of MOCS3 protein as an active ingredient. The MOCS3 protein activity inhibitor is
An antibody against the MOCS3 protein,
The cancer therapeutic agent of Claim 3 containing this. The cancer therapeutic agent according to any one of claims 1 to 4, wherein the cancer is colorectal cancer or cervical cancer. A method of screening for an expression inhibitor of MOCS3 gene,
(A) contacting a test compound with a cell expressing the MOCS3 gene;
(B) A screening method comprising the step of measuring the expression level of the MOCS3 gene, and (c) selecting a compound that decreases the expression level as compared with the case where the test compound is not contacted. A method for screening for an activity inhibitor of MOCS3 protein, comprising:
(A) contacting the MOCS3 protein with a test compound;
(B) A screening method comprising a step of measuring the binding activity between the MOCS3 protein and a test compound, and (c) selecting a compound that binds to the MOCS3 protein. The method according to claim 6 or 7, wherein the cancer is colorectal cancer or cervical cancer. Antibodies against MOCS3 protein. A cancer therapeutic agent comprising the antibody according to claim 9. The cancer therapeutic agent according to claim 10, further comprising a vector carrying a radioisotope, a therapeutic protein, a low molecular drug, or a therapeutic gene. The cancer therapeutic agent according to claim 10 or 11, wherein the cancer is colon cancer or cervical cancer. A cancer diagnostic agent comprising the antibody according to claim 9. A cancer diagnostic agent comprising a base sequence capable of hybridizing under stringent hybridization conditions to the MOCS3 gene or a partial base sequence thereof. The cancer diagnostic agent according to claim 13 or 14, wherein the cancer is colon cancer. A kit for cancer diagnosis containing the antibody according to claim 9. A cancer diagnostic kit comprising a polynucleotide comprising a base sequence capable of hybridizing under stringent hybridization conditions to the MOCS3 gene or a part of the base sequence. The cancer diagnostic kit according to claim 16 or 17, wherein the cancer is colon cancer. A method for detecting and / or quantifying MOCS3 protein or MOCS3 gene in a biological sample derived from a subject as a cancer marker. 20. The method of claim 19, wherein the biological sample is whole blood, serum, or plasma. The method according to claim 19 or 20, wherein the MOCS3 protein is detected and / or quantified using a mass spectrometer. The method according to any one of claims 19 to 21, wherein the MOCS3 protein is detected and / or quantified using an anti-MOCS3 antibody. (A) contacting a biological sample derived from a subject with an antibody against the MOCS3 protein, and (b) detecting and / or quantifying the binding between the antibody and the MOCS3 protein in the sample,
23. The method of claim 22 comprising: (A) contacting a biological sample derived from a subject with a polynucleotide comprising a base sequence capable of hybridizing to the base sequence of the MOCS3 gene or a fragment thereof under stringent hybridization conditions; and (b) in the sample. Detecting and / or quantifying hybridization of said polynucleotide with MOCS3 gene or a fragment thereof,
21. A method according to claim 19 or 20, comprising: The method according to any one of claims 19 to 24 for use in diagnosis of cancer. 26. The method of claim 25, wherein the cancer is colon cancer.

Images